Finex logo
Finex Intelligence

Market Signal Briefing

Wire-ready dashboard awaiting your first source connection.

Last news saved at Mar 30, 13:54 1mo ago Cron last ran Mar 30, 13:54 1mo ago Awaiting first source
Switch language
91,488 Stories ingested Auto-fetched market intel nonstop.
0 Distinct tickers Add sources to start tracking symbols
Trending sources Waiting for fresh intel
Hot tickers Surfacing from current coverage
Details Saved Published Title Source Tickers
2025-10-31 13:16 6mo ago
2025-10-31 09:06 6mo ago
Colgate-Palmolive (CL) Surpasses Q3 Earnings Estimates stocknewsapi
CL
Colgate-Palmolive (CL - Free Report) came out with quarterly earnings of $0.91 per share, beating the Zacks Consensus Estimate of $0.89 per share. This compares to earnings of $0.91 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of +2.25%. A quarter ago, it was expected that this consumer products maker would post earnings of $0.89 per share when it actually produced earnings of $0.92, delivering a surprise of +3.37%.

Over the last four quarters, the company has surpassed consensus EPS estimates four times.

Colgate-Palmolive, which belongs to the Zacks Consumer Products - Staples industry, posted revenues of $5.13 billion for the quarter ended September 2025, missing the Zacks Consensus Estimate by 0.07%. This compares to year-ago revenues of $5.03 billion. The company has topped consensus revenue estimates two times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Colgate-Palmolive shares have lost about 15.8% since the beginning of the year versus the S&P 500's gain of 16%.

What's Next for Colgate-Palmolive?While Colgate-Palmolive has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Colgate-Palmolive was unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.94 on $5.15 billion in revenues for the coming quarter and $3.67 on $20.31 billion in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Consumer Products - Staples is currently in the bottom 17% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

Purple Innovation (PRPL - Free Report) , another stock in the same industry, has yet to report results for the quarter ended September 2025.

This company is expected to post quarterly loss of $0.09 per share in its upcoming report, which represents a year-over-year change of -12.5%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.

Purple Innovation's revenues are expected to be $123.1 million, up 3.8% from the year-ago quarter.
2025-10-31 13:16 6mo ago
2025-10-31 09:06 6mo ago
Oil States International (OIS) Lags Q3 Earnings and Revenue Estimates stocknewsapi
OIS
Oil States International (OIS - Free Report) came out with quarterly earnings of $0.08 per share, missing the Zacks Consensus Estimate of $0.1 per share. This compares to earnings of $0.04 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of -20.00%. A quarter ago, it was expected that this energy services company would post earnings of $0.09 per share when it actually produced earnings of $0.09, delivering no surprise.

Over the last four quarters, the company has surpassed consensus EPS estimates two times.

Oil States International, which belongs to the Zacks Oil and Gas - Mechanical and and Equipment industry, posted revenues of $165.18 million for the quarter ended September 2025, missing the Zacks Consensus Estimate by 1.4%. This compares to year-ago revenues of $174.35 million. The company has not been able to beat consensus revenue estimates over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Oil States International shares have added about 34% since the beginning of the year versus the S&P 500's gain of 16%.

What's Next for Oil States International?While Oil States International has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Oil States International was unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.17 on $186.1 million in revenues for the coming quarter and $0.42 on $678.99 million in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Oil and Gas - Mechanical and and Equipment is currently in the top 39% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

Another stock from the same industry, National Energy Services Reunited (NESR - Free Report) , has yet to report results for the quarter ended September 2025.

This company is expected to post quarterly earnings of $0.15 per share in its upcoming report, which represents a year-over-year change of -51.6%. The consensus EPS estimate for the quarter has been revised 25% lower over the last 30 days to the current level.

National Energy Services Reunited's revenues are expected to be $291.25 million, down 13.4% from the year-ago quarter.
2025-10-31 13:16 6mo ago
2025-10-31 09:06 6mo ago
Church & Dwight (CHD) Q3 Earnings and Revenues Top Estimates stocknewsapi
CHD
Church & Dwight (CHD - Free Report) came out with quarterly earnings of $0.81 per share, beating the Zacks Consensus Estimate of $0.73 per share. This compares to earnings of $0.79 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of +10.96%. A quarter ago, it was expected that this maker of household and personal products would post earnings of $0.85 per share when it actually produced earnings of $0.94, delivering a surprise of +10.59%.

Over the last four quarters, the company has surpassed consensus EPS estimates three times.

Church & Dwight, which belongs to the Zacks Consumer Products - Staples industry, posted revenues of $1.59 billion for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 3.32%. This compares to year-ago revenues of $1.51 billion. The company has topped consensus revenue estimates three times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Church & Dwight shares have lost about 21.9% since the beginning of the year versus the S&P 500's gain of 16%.

What's Next for Church & Dwight?While Church & Dwight has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Church & Dwight was unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.88 on $1.63 billion in revenues for the coming quarter and $3.46 on $6.14 billion in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Consumer Products - Staples is currently in the bottom 17% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

Leslie's, Inc. (LESL - Free Report) , another stock in the same industry, has yet to report results for the quarter ended September 2025.

This company is expected to post quarterly earnings of $1.10 per share in its upcoming report, which represents a year-over-year change of +175%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.

Leslie's, Inc.'s revenues are expected to be $368.43 million, down 7.4% from the year-ago quarter.
2025-10-31 13:16 6mo ago
2025-10-31 09:06 6mo ago
3 Fertilizer Stocks to Keep an Eye on in a Challenging Industry stocknewsapi
CF NTR YARIY
The Zacks Fertilizers industry is challenged by elevated costs of key raw materials, partly due to the Russia-Ukraine war, which has put pressure on the margins of companies in this space. Weaker crop prices and higher costs are also likely to result in farmers reducing application rates, partly due to affordability issues, leading to weaker fertilizer demand.

  However, improved fertilizer prices augur well for the industry players. Fertilizer players such as Nutrien Ltd. (NTR - Free Report) , CF Industries Holdings, Inc. (CF - Free Report) and Yara International ASA (YARIY - Free Report) are worth a look, notwithstanding the near-term headwinds.

About the Industry
The Zacks Fertilizers industry comprises producers, distributors and marketers of crop nutrients for the global agriculture industry. Companies in this space offer nutrients such as phosphates (including diammonium phosphate, monoammonium phosphate and phosphoric acid), potash and nitrogen (including urea, ammonia and urea ammonium nitrate) fertilizers. They also provide other nitrogen products to help farmers maximize crop yield. Crop nutrients are essential to drive agricultural productivity and boost the natural fertility of the soil. Demand for these nutrients is being supported by the need to increase the production of grains to address rising food consumption globally. Moreover, the constant need of growers to nourish their crops, replenish nutrients in the soil following a harvest and boost yields to feed a growing global population drives the consumption of fertilizers.

What's Shaping the Future of the Fertilizers Industry?
Elevated Input Costs a Concern: Increased prices of major raw materials pose a headwind to the companies in this space. Prices of both sulfur and ammonia — key inputs for the production of phosphate — remain elevated. Supply disruptions from Russia amid the war with Ukraine contributed to the rise in prices of both sulfur and ammonia. Plant shutdowns and maintenance also led to a tight supply of these raw materials, which, coupled with strong demand, pushed up their prices. Rising natural gas prices, a key feedstock for nitrogen fertilizer, are also a concern. Higher raw material costs have led to an increase in production costs. As such, fertilizer makers are likely to face short-term margin pressure associated with higher input costs.

Reduced Affordability to Dampen Fertilizer Demand: While farm income is projected to rise this year, growers face challenges from increased fertilizer prices, higher input and other costs and lower crop commodity prices. Escalating costs are likely to result in farmers reducing fertilizer applications or switching to less fertilizer-intensive crops, leading to softer demand. Per the U.S. Department of Agriculture (“USDA”), net farm income is projected to climb 40.7% year over year to $179.8 billion this year, driven by a significant increase in government payments. However, this reflects a decline from USDA’s February 2025 projection of $180.1 billion. Also, farmers face challenges from lower expected crop receipts in 2025. USDA sees crop cash receipts to decline 2.5% year over year in 2025 due to lower prices for most crops. Prices of corn, soybean and wheat have declined from the multi-year highs reached in 2022, and remain lower this year due to oversupply.

Higher Fertilizer Prices Augur Well: Prices of phosphate and potash retreated in the back half of 2022 from their peak levels attained in the first half, impacted by the Russia-Ukraine war and disruptions due to the sanctions in Belarus. Global nitrogen prices also declined due to higher global supply, driven by increased global operating rates resulting from lower global energy costs. Prices remain depressed in 2023 and 2024, weighing on the profitability of fertilizer companies. On a positive note, strong demand and supply tightness have led to an uptick in fertilizer prices this year, with phosphate prices seeing a notable increase. Higher fertilizer prices are expected to drive top-line and margin expansion for companies in this space over the near term.

Zacks Industry Rank Reflects Downbeat Prospects
The Zacks Fertilizers industry is part of the broader Zacks Basic Materials sector. It carries a Zacks Industry Rank #207, which places it in the bottom 15% of more than 250 Zacks industries.

The group’s Zacks Industry Rank, which is basically the average of the Zacks Rank of all the member stocks, indicates a bleak near term. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

Before we present a few stocks that you may want to consider for your portfolio, let’s take a look at the industry’s recent stock market performance and valuation picture.

Industry Underperforms S&P 500
The Zacks Fertilizers industry has underperformed the Zacks S&P 500 composite while outperforming the broader Zacks Basic Materials sector over the past year.

The industry has gained 13.5% over this period against the S&P 500’s rise of 22.7% and the broader sector’s increase of 8%.

One-Year Price Performance

Industry's Current Valuation
On the basis of the trailing 12-month enterprise value-to EBITDA (EV/EBITDA) ratio, which is a commonly used multiple for valuing fertilizer stocks, the industry is currently trading at 5.55X compared with the S&P 500’s 19.18X and the sector’s 13.91X.

In the past five years, the industry has traded as high as 18.05X and as low as 4.55X, with a median of 10.4X, as the chart below shows.

Enterprise Value/EBITDA (EV/EBITDA) Ratio

Enterprise Value/EBITDA (EV/EBITDA) Ratio
 
3 Fertilizer Stocks to Keep a Close Eye on
Nutrien: Canada-based Nutrien is a leading provider of crop inputs and services. The company is benefiting from higher demand for crop nutrients, backed by supportive global agriculture markets. It is seeing strong demand in its major markets, particularly North America. NTR is also gaining from acquisitions, cost efficiency and increased adoption of its digital platform. The company also continues to expand its footprint in Brazil through acquisitions. Cost and operational efficiency initiatives are also expected to aid the company’s performance. NTR remains focused on lowering the cost of production in the potash business. The company has announced several strategic actions to reduce its controllable costs and boost free cash flow.

Nutrien currently carries a Zacks Rank #3 (Hold). NTR has expected earnings growth of 31.4% for 2025. The Zacks Consensus Estimate for 2025 earnings has been revised 5.1% upward over the past 60 days. It also has an expected long-term earnings per share growth rate of 14.5%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Price and Consensus: NTR

CF Industries: Illinois-based CF Industries is a leading global manufacturer of nitrogen and hydrogen products for fertilizer, clean energy, emissions reduction and other industrial applications. It is gaining from higher nitrogen fertilizer demand in the major markets such as North America, Brazil and India. CF is seeing higher nitrogen demand for industrial uses in North America. CF remains committed to boosting shareholders’ value by leveraging strong cash flows. The company is also taking action to de-leverage its balance sheet.

CF Industries, currently with a Zacks Rank #3, has an expected earnings growth rate of 23.7% for 2025. CF’s earnings beat the Zacks Consensus Estimate in each of the last four quarters at an average of 25.3%.

Price and Consensus: CFYara International: Norway-based Yara International is a leading global producer and supplier of mineral fertilizers. It has industry-leading experience in ammonia development, production, operations and distribution. A favorable nitrogen demand environment bodes well for YARIY. Cost reductions and actions to strengthen the balance sheet are expected to boost the company’s profitability and cash flows. YARIY also remains focused on rewarding its shareholders by leveraging strong cash flows.

Yara International presently has a Zacks Rank #3. It has an expected earnings growth rate of 149.3% for 2025. YARIY has a trailing four-quarter earnings surprise of roughly 58.4%, on average.

Price and Consensus: YARIY
2025-10-31 13:16 6mo ago
2025-10-31 09:06 6mo ago
Activist fund Ananym steps up calls for LKQ to sell European business stocknewsapi
LKQ
SummaryCompaniesAnanym redoubles push to persuade LKQ to sell European businessHedge fund says there are buyers interested in the European businessProceeds from a sale could be used to reduce leverage, buy back stockNEW YORK, Oct 31 (Reuters) - Ananym Capital has intensified its call for auto-parts supplier LKQ

(LKQ.O), opens new tab to sell its European business, stressing that there are interested buyers and that the proceeds could be used to buy back shares, according to a letter to LKQ's board on Friday that was seen by Reuters.

The letter, following close on the heels of the company's third-quarter earnings report the day before, pressed the activist hedge fund's point that keeping the European and North American businesses together makes little sense.

Sign up here.

"While management continues to pursue the arduous task of trying to integrate the disparate collection of businesses that comprise the EU business, LKQ continues to suffer from a substantial sum-of-the-parts discount and to dramatically lag its peers in share price performance,"

the hedge fund wrote, opens new tab.

A representative for LKQ was not immediately available to comment.

On Thursday's earnings call with analysts, CEO Justin Jude said: "The challenges in Europe affect the entire industry but LKQ excels in such environments, as shown by our own success in North America. Having integrated businesses in tough settings before, I am confident we can achieve similar results in Europe."

The strong North America performance powered a more than 5% rise in LKQ's stock during Thursday's session, but its close at $31.16 left it down more than 16% for the past 12 months.

Ananym's letter noted that the total return on stock in LKQ, which has a market value of $8 billion, has lagged its proxy peers by 33% over the last 12 months, by 113% over the last five years, and by 253% over the last decade.

It added that, instead of trying to integrate 20 ERP software systems across 900 locations in 18 different countries in Europe, management should talk to potential buyers who could handle the integration and free up LKQ executives to concentrate on running its "crown jewel NA (North America) collision business."

Management could use the proceeds from selling the European business to reduce leverage and buy back shares, which would create more benefits for shareholders than trying to run the European business in the coming years, the hedge fund said.

Ananym has been holding discussions with Chicago-headquartered LKQ in recent months and has been largely complimentary of the company's CEO, Justin Jude, who was named to the position in July 2024.

But in late summer, the hedge fund stepped up its push for a separation or sale of the European business after disappointing second-quarter earnings, when investors pushed the stock price down more than 20%.

The company has taken steps to simplify its portfolio, and in August announced the sale of its self-service segment to private-equity firm Pacific Avenue Capital Partners.

Ananym was founded last year by Charlie Penner, the architect of a massive three-board-seat victory at Exxon Mobil

(XOM.N), opens new tab in 2021, and former P2 partner Alex Silver.

Reporting by Svea Herbst-Bayliss; Editing by Edmund Klamann

Our Standards: The Thomson Reuters Trust Principles., opens new tab
2025-10-31 13:16 6mo ago
2025-10-31 09:07 6mo ago
Bavarian Nordic shareholders are reminded of expiry of the offer period regarding the takeover offer from consortium consisting of Nordic Capital and Permira stocknewsapi
BVNKF BVNRY
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION

COPENHAGEN, Denmark, 31 October, 2025 – Reference is made to the company announcements dated 26 August 2025 (no. 24/2025), 29 September 2025 (no. 27/2025), 15 October 2025 (no. 31/2025), and 21 October 2025 (no. 33/2025) regarding the all-cash voluntary recommended public takeover offer to acquire all of the issued and outstanding shares (except treasury shares) in Bavarian Nordic A/S ("Bavarian Nordic") by Innosera ApS (the "Offeror"), a company controlled by Nordic Capital Fund XI1 and funds managed and advised by Permira Beteiligungsberatung GmbH (the "Offer"). The Offeror has today published an announcement reminding shareholders of Bavarian Nordic of the expiry of the offer period on 5 November 2025 at 11:59 p.m (CET). Shareholders wishing to accept the Offer are advised to take early action, as the deadline for the individual account holding institutions' receipt of acceptances may be earlier than 5 November 2025.

As announced on 9 October 2025 (company announcement no. 29/2025), the Offeror has obtained all regulatory approvals to satisfy the regulatory conditions of the Offer. Completion of the Offer however remains subject to satisfaction of the remaining conditions, including the minimum acceptance condition of 66 2/3% of the shares in Bavarian Nordic (excluding treasury shares), set out in the offer document dated 26 August 2025, as amended by the supplements dated 29 September 2025, 15 October 2025 and 21 October 2025, (the initial offer document as amended by said supplements, the “Offer Document”)

The Offeror has informed that since the announcement dated 21 October 2025, the Offeror has obtained undertakings from global institutional investors and increased commitments to accept the Offer representing an additional 4.8% of Bavarian Nordic’s share capital. The 4.8% reflects solely undertakings from these global institutional investors and does not include acceptances submitted by other investors since 21 October 2025.

Acceptance of the Offer must be submitted via the shareholder's own custodian bank or other account holding institution before the expiry of the offer period. Shareholders may accept the Offer online via their custodian bank’s or other account holding institution's web banking solution or by using the acceptance form attached to the Offer Document and the Supplements.

Offer-related documents, and English translations of such documents, are, subject to certain restrictions, available on Bavarian Nordic's website www.bavarian-nordic.com.

Bavarian Nordic shareholders are advised to read the Offer Document, and the statements dated 26 August 2025 and 16 October 2025, whereby the Board of Directors2 decided to recommend the shareholders of Bavarian Nordic to accept the Offer, in their respective entirety before deciding whether to accept the Offer.

Contact investors:
Europe: Disa Tuominen, IR Manager, [email protected]
US: Graham Morrell, Gilmartin Group, [email protected], Tel: +1 781 686 9600

Contact media:
Nicole Seroff, Vice President Corporate Communications, [email protected], Tel: +45 53 88 06 03

Company Announcement no. 36 / 2025

Attachments:
Reminder of expiry of the offer period on 5 November 2025 and update on undertakings received for the board-recommended public tender offer to the shareholders of Bavarian Nordic A/S

About Bavarian Nordic
Bavarian Nordic is a global vaccine company with a mission to improve health and save lives through innovative vaccines. We are a preferred supplier of mpox and smallpox vaccines to governments to enhance public health preparedness and have a leading portfolio of travel vaccines. For more information, visit www.bavarian-nordic.com.

DISCLAIMERS
This announcement is for informational purposes only and does not constitute an offer to purchase or a solicitation of an offer to sell any securities and is neither a tender offer document nor a prospectus for the purposes of EU regulation 2017/1129, and as such does not constitute or form part of an offer or invitation to make a sales offer in any jurisdiction.

This announcement is not directed at shareholders of Bavarian Nordic resident in any jurisdiction in which the submission of the Offer, or acceptance thereof, or this announcement would contravene the law of such jurisdiction. Accordingly, neither this announcement nor any other material regarding the Offer may be distributed in any jurisdiction outside of Denmark or United States, if such distribution would require any registration, qualification, or other requirement in respect of any offer to purchase or sell securities or distribute documents or advertisements in respect thereof. Any person acquiring possession of this announcement or any other document referring to the Offer is expected and assumed to obtain on his or her own accord any necessary information on any applicable restrictions and to comply with such restrictions.

This announcement does not constitute an offer or invitation to purchase any securities in Bavarian Nordic or a solicitation of an offer to buy any securities, pursuant to the Offer or otherwise. The Offer is made solely by means of the Offer Document (as amended by the supplements) approved by the Danish Financial Supervisory Authority, which contains the full terms and conditions of the Offer, including details of how the Offer may be accepted. Shareholders in Bavarian Nordic are advised to read the Offer Document (as amended by the supplements) and the related documents as they contain important information.

The Offer is subject to the laws of Denmark. The Offer Document (as amended by the supplements), the board statements and this announcement have been drawn up in the Danish and English languages. In the event of any discrepancy between the two language versions of the Offer Document, the supplements, and the board statements, the Danish language version will prevail. The Offer relates to the securities of a Danish company and is subject to the disclosure requirements applicable under Danish law, which may be different in material aspects from those applicable in the United States.

For shareholders residing or precedent in the United States, please see notice below.

Forward looking statements
This announcement may contain, in addition to historical information, forward-looking statements related to the proposed tender offer. When used in this announcement, the words “aims,” “anticipates,” “assumes,” “believes,” “could,” “estimates,” “expects,” “intends,” “may,” “plans,” “should,” “will,” “would” and similar expressions as they relate to the Offeror and Bavarian Nordic or the Offer identify certain of these forward-looking statements. Other forward-looking statements can be identified in the context in which the statements are made. Such statements are based on the Offeror’s and management’s current expectations and are subject to a number of uncertainties and risks, which could cause actual results to differ materially from those described in the forward-looking statements. All forward-looking statements included in this announcement are based on information available to Bavarian Nordic as of the date of this announcement, and except to the extent Bavarian Nordic may be required to update such information under any applicable securities laws, Bavarian Nordic assumes no obligation to update such forward-looking statements.

Restricted jurisdictions
The Offer is not made, and the Bavarian Nordic shares will not be accepted by the Offeror for purchase from or on behalf of persons, in any jurisdiction in which the making or acceptance thereof would not be in compliance with the securities or other laws or regulations of such jurisdiction. Persons obtaining this announcement and/or into whose possession this announcement comes are required to take due note and observe all such restrictions and obtain any necessary authorizations, approvals or consents. Neither Bavarian Nordic nor any of its advisors accepts any liability for any violation by any person of any such restriction. Any person (including, without limitation, custodians, nominees and trustees) who intends to forward this announcement to any jurisdiction outside Denmark should inform themselves of the laws of the relevant jurisdiction, before taking any action. The distribution of this announcement in jurisdictions other than Denmark may be restricted by law, and, therefore, persons who come into possession of this announcement should inform themselves about and observe such restrictions. Any failure to comply with any such restrictions may constitute a violation of the securities laws and regulations of any such jurisdiction.

Notice to shareholders in the United States
The Offer is subject to the laws of Denmark. The Offer relates to the securities of a Danish company and is subject to the disclosure requirements applicable under Danish law, which may be different in material respects from those applicable in the United States.

The Offer is being made in the United States in compliance with Section 14(e) of, and applicable provisions of Regulation 14E promulgated under, the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act"), and otherwise in accordance with the requirements of Danish law. The Offer is not subject to Section 14(d)(1) of, or Regulation 14D promulgated under, the Exchange Act. The Offer is subject to disclosure and procedural requirements that may be different from those applicable to U.S. domestic tender offers, including with respect to withdrawal rights, the Offer timetable, notices of extensions, announcements of results, settlement procedures (including as regards to the time when payment of the consideration is rendered), and waivers of conditions. In addition, any financial information included in the Offer documents may not have been prepared in accordance with generally accepted accounting principles in the United States and thus may not be comparable to financial information relating to U.S. companies. Shareholders whose place of residence, seat, or habitual residence is in the United States (“U.S. Shareholders”) are encouraged to consult with their own advisors regarding the Offer.

The Offer is being made to U.S. Shareholders on the same terms and conditions as those made to all other shareholders to whom the Offer is made. Any information documents, including the offer to purchase, are disseminated to U.S. Shareholders on a basis reasonably comparable to the method that such documents are provided to other shareholders.

It may be difficult for U.S. Shareholders to enforce certain rights and claims they may have arising in connection with the Offer under U.S. securities laws, since the Offeror and Bavarian Nordic are located in non-U.S. jurisdictions, and some or all of their respective officers and directors are residents of non-U.S. jurisdictions. U.S. Shareholders may not be able to sue the Offeror or Bavarian Nordic and/or their respective officers or directors in a non-U.S. court for violations of U.S. securities laws. Further, it may not be possible to compel the Offeror or their respective affiliates, as applicable, to subject themselves to the judgment of a U.S. court.

The receipt of cash pursuant to the Offer by a U.S. Shareholder may be a taxable transaction for U.S. federal income tax purposes and under applicable U.S. state and local, as well as foreign and other, tax laws. Each U.S. Shareholder is urged to consult its independent professional advisor immediately regarding the tax consequences to such U.S. Shareholder of accepting the Offer.

In accordance with customary Danish practice and to the extent permitted by applicable law, including Rule 14e-5(b) of the Exchange Act, the Offeror or any affiliates or nominees or brokers of the foregoing (acting as agents or in a similar capacity), may from time to time make certain purchases of, or arrangements to purchase, shares (or any securities that are convertible into, exchangeable for or exercisable for such shares) outside of the U.S., other than pursuant to the Offer, before or during the period in which the Offer remains open for acceptance. These purchases may occur either in the open market at prevailing prices or in private transactions at negotiated prices. If, prior to completion of the Offer, the Offeror or any affiliates or any nominee or broker of the foregoing acquires Shares at a higher price than the offer price, the Offeror will increase the offer price correspondingly as required by applicable law. In addition, affiliates of the financial advisors to the Offeror may also engage in ordinary course trading activities in securities of Bavarian Nordic, which may include purchases or arrangements to purchase such securities as long as such purchases or arrangements are in compliance with applicable law and regulation. Any information about such purchases will be announced through Nasdaq Copenhagen and relevant electronic media if, and to the extent, such announcement is required under applicable law or regulation.

Neither the U.S. Securities and Exchange Commission nor any securities commission or other regulatory authority in any state of the United States has approved or declined to approve the Offer or any offer documents, passed upon the fairness or merits of the Offer, or provided an opinion as to the accuracy or completeness of this announcement or any other documents regarding the Offer. Any declaration to the contrary constitutes a criminal offense in the United States.

This announcement is not intended for distribution in any jurisdiction where such distribution would violate applicable law or regulation. The Offer is being made only through the official offer documents and only to such persons and in such jurisdictions as permitted under applicable law. No recommendation is made as to whether holders of securities should tender their securities in connection with the Offer. Holders of securities should consult their own financial, legal, and tax advisors before making any decision regarding the Offer.

1 “Nordic Capital Fund XI” refers to Nordic Capital Epsilon SCA, SICAV-RAIF (acting through its general partner Nordic Capital Epsilon GP SARL) for and on behalf of its compartment Nordic Capital Epsilon SCA, SICAV-RAIF - Compartment 2. “Nordic Capital” refers to, depending on the context, any, or all, Nordic Capital branded entities, vehicles, structures, and associated entities. The general partners and/or delegated portfolio managers of Nordic Capital’s entities and vehicles are advised by several non-discretionary sub-advisory entities, any or all of which are referred to as “Nordic Capital Advisors”.

2 Maria Montserrat Montaner Picart (the "Conflicted Director"), who is affiliated with Nordic Capital, has not taken part in the Board of Directors' deliberations and otherwise Bavarian Nordic's handling of the transactions contemplated by the announcement agreement and the Offer, including the negotiations leading to the entering into of the announcement agreement. Accordingly, any reference to Bavarian Nordic's Board of Directors in this company announcement shall, unless otherwise so specifically stated, be understood to exclude the Conflicted Director.

Company Announcement no. 36 / 2025

Reminder of expiry of the offer period on 5 November 2025 and update on undertakings received for the board-recommended public tender offer to the shareholders of Bavarian Nordic A/S
2025-10-31 13:16 6mo ago
2025-10-31 09:10 6mo ago
Eos Energy Secures Strategic 228 MWh Order from Frontier Power Under Existing 5 GWh Framework Agreement & Achieves Final Cerberus Milestone stocknewsapi
EOSE
Order strengthens growing partnership to deploy long-duration energy storage across multiple markets

October 31, 2025 09:10 ET

 | Source:

Eos Energy Enterprises, Inc.

PITTSBURGH, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Eos Energy Enterprises, Inc. (NASDAQ: EOSE) ("Eos" or the “Company”), an American energy company and the leading innovator in designing, sourcing, manufacturing, and providing zinc-based battery energy storage systems (BESS) and Frontier Power Ltd. (“Frontier”), a leading UK-based energy developer, today announced a strategic 228 megawatt-hour (MWh) order to deploy Eos Z3™ energy storage systems across Frontier’s expanding portfolio of storage and grid-reliability projects.

The 228 MWh order – the first to be converted under the companies’ 5 GWh framework agreement announced in April 2025 – marks a significant milestone in a growing partnership focused on scaling alternative, long-duration energy storage to strengthen grid reliability across multiple markets.

“This order reflects continued confidence in Eos’ zinc technology and the strength of our partnership with Frontier,” said Nathan Kroeker, Eos Chief Commercial Officer. “Together, we’re demonstrating that long-duration storage is ready to scale and play a critical role in delivering reliable dispatchable power.”

Frontier will deploy Eos’ Z3™ energy storage systems, featuring the Company’s proprietary battery management system, software, controls and analytics platform – DawnOS™ – to validate performance and reliability in diverse grid environments. This provides a unique opportunity to showcase Eos’ technology ahead of Frontier’s upcoming projects under Ofgem’s Cap-and-Floor program.

Frontier recently advanced 11 gigawatt-hours (GWh) of long-duration storage projects to the second round of the program, all incorporating Eos’ technology and more than double the original commitment. This milestone highlights the growing market demand for 8-hour-plus storage and reinforces confidence in the companies’ joint ability to deliver commercially viable, large-scale solutions.

“Our partnership with Eos goes beyond a single project – it’s about building a platform for long-duration storage at scale,” said Humza Malik, Frontier Chief Executive Officer. “Together, we’re demonstrating how innovative, safe, and sustainable zinc technology can support renewable growth and deliver dependable, flexible power for the grid of the future.”

Eos’ Z3™ technology builds on the company’s proven zinc-based chemistry, offering enhanced energy density, extended duration, and a safe, non-flammable solution ideal for long-life, grid-scale applications. As the partnership grows, Eos and Frontier are positioned to accelerate deployment of long-duration energy storage across key international markets, supporting renewable integration, grid stability, and global energy security.

The announcement coincides with the Company also achieving its final cash receipt milestone previously agreed upon between Eos and an affiliate of Cerberus Capital Management LP (Cerberus) as part of Cerberus’s strategic investment in the Company. No additional preferred stock or warrants will be issued to Cerberus at this time.

About Eos Energy Enterprises

Eos is accelerating the shift to American energy independence with positively ingenious solutions that transform how the world stores power. The Company’s BESS features the innovative Znyth™ technology, a proven chemistry with readily available non-precious earth components, that is the pre-eminent safe, non-flammable, secure, stable, and scalable alternative to conventional lithium-ion technology. The Company’s BESS is ideal for utility-scale, microgrid, commercial, and industrial long-duration energy storage applications (i.e., 4 to 16+ hours) and provides customers with significant operational flexibility to cost effectively address current and future increased grid demand and complexity. For more information about Eos (NASDAQ: EOSE), visit eose.com.

Contacts        
Investors:  [email protected]
Media:  [email protected]

Forward Looking Statements

Except for the historical information contained herein, the matters set forth in this press release are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements that refer to outlook, projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intends," "may," "might," "plan," "possible," "potential," "predict," "project," "should," "would" and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are based on our management’s beliefs, as well as assumptions made by, and the information currently available to, them. Because such statements are based on expectations as to future financial and operating results and are not statements of fact, actual results may differ materially from those projected.

Factors which may cause actual results to differ materially from current expectations include, but are not limited to: changes adversely affecting the business in which we are engaged; our ability to forecast trends accurately; our ability to generate cash, service indebtedness and incur additional indebtedness; our ability to achieve the operational milestones on the delayed draw term loan; our ability to raise financing in the future; risks associated with the credit agreement with Cerberus, including risks of default, dilution of outstanding Common Stock, consequences for failure to meet milestones and contractual lockup of shares; our customers’ ability to secure project financing; the amount of final tax credits available to our customers or to Eos pursuant to the Inflation Reduction Act; the timing and availability of future funding under the Department of Energy Loan Facility; our ability to continue to develop efficient manufacturing processes to scale and to forecast related costs and efficiencies accurately; fluctuations in our revenue and operating results; competition from existing or new competitors; our ability to convert firm order backlog and pipeline to revenue; risks associated with security breaches in our information technology systems; risks related to legal proceedings or claims; risks associated with evolving energy policies in the United States and other countries and the potential costs of regulatory compliance; risks associated with changes to the U.S. trade environment; our ability to maintain the listing of our shares of common stock on NASDAQ; our ability to grow our business and manage growth profitably, maintain relationships with customers and suppliers and retain our management and key employees; risks related to the adverse changes in general economic conditions, including inflationary pressures and increased interest rates; risk from supply chain disruptions and other impacts of geopolitical conflict; changes in applicable laws or regulations; the possibility that Eos may be adversely affected by other economic, business, and/or competitive factors; other factors beyond our control; risks related to adverse changes in general economic conditions; and other risks and uncertainties.

The forward-looking statements contained in this press release are also subject to additional risks, uncertainties, and factors, including those more fully described in the Company’s most recent filings with the Securities and Exchange Commission, including the Company’s most recent Annual Report on Form 10-K and subsequent reports on Forms 10-Q and 8-K. Further information on potential risks that could affect actual results will be included in the subsequent periodic and current reports and other filings that the Company makes with the Securities and Exchange Commission from time to time. Moreover, the Company operates in a very competitive and rapidly changing environment, and new risks and uncertainties may emerge that could have an impact on the forward-looking statements contained in this press release.

Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and, except as required by law, the Company assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.
2025-10-31 13:16 6mo ago
2025-10-31 09:10 6mo ago
Meta Stock Drops 10%, How Low Can It Go? stocknewsapi
META
Meta Platforms (META) stock fell 11.3% in a single day after investors reacted negatively to the company’s plans to meaningfully increase capital spending next year to support its growing AI compute needs.

A photograph taken during the World Economic Forum (WEF) annual meeting in Davos on January 19, 2025, shows the logo of Meta, the US company that owns and operates Facebook, Instagram, Threads, and WhatsApp. (Photo by Fabrice COFFRINI / AFP) (Photo by FABRICE COFFRINI/AFP via Getty Images)

AFP via Getty Images

We believe that the stock appears to be fairly valued right now, although past patterns indicate you could gain by purchasing when prices drop. Consider the following information:

Size: Meta Platforms is valued at $1.7 Trillion, with $189 Billion in revenue, and is currently trading at $666.47.Fundamentals: Revenue growth over the last 12 months is at 21.3%, with an operating margin of 43.2%.Liquidity: It has a Debt to Equity ratio of 0.03 and a Cash to Assets ratio of 0.15.Valuation: The stock of Meta Platforms is presently trading at a P/E multiple of 28.7 and a P/EBIT multiple of 19.7.It has shown a median return of 74.5% within a year after significant drops since 2010. Refer to META Dip Buy Analysis.While we prefer to purchase on dips when the fundamentals align – for META, see Buy or Sell META Stock – we remain cautious about catching falling knives. Specifically, it is essential to consider if circumstances worsen, and META declines by another 20-30% to $467 levels, would we be able to retain the stock? What is the worst-case scenario? We refer to it as downturn resilience. It turns out that the stock has performed worse than the S&P 500 index during various economic recessions. We assess this by evaluating (a) the magnitude of the stock's decline and (b) the speed of its recovery.

Investing in a single stock can be risky, but there is significant value in a broader, diversified strategy that we embrace with the Trefis High Quality Portfolio. This is one approach to analyze stocks. The Trefis High Quality Portfolio assesses a lot more and aims to mitigate stock-specific risk while providing upside potential.

Below are the specifics, but first, as a brief overview: META offers products that allow individuals to connect and share through devices, including mobile phones, PCs, VR headsets, wearables, and augmented reality, facilitating connection anytime and anywhere.

2022 Inflation Shock

META stock declined 76.7% from a high of $382.18 on 7 September 2021 to $88.91 on 3 November 2022, compared to a peak-to-trough decrease of 25.4% for the S&P 500.However, the stock fully regained its pre-Crisis peak by 19 January 2024.Since then, the stock rose to a high of $790.00 on 12 August 2025 and is currently valued at $666.47.Inflation Shock

Trefis

2020 Covid Pandemic

META stock fell 34.6% from a peak of $223.23 on 29 January 2020 to $146.01 on 16 March 2020, compared to a peak-to-trough decline of 33.9% for the S&P 500.However, the stock completely recovered to its pre-Crisis height by 20 May 2020.2020

Trefis

2018 Correction

META stock declined 43.0% from a peak of $217.50 on 25 July 2018 to $124.06 on 24 December 2018, compared to a peak-to-trough decrease of 19.8% for the S&P 500.However, the stock fully returned to its pre-Crisis peak by 9 January 2020.2018

Trefis

It is important to remain aware of how low META could potentially fall during a recession. Additionally, you should assess how the stock performed when evaluated against the Trefis High Quality (HQ) Portfolio, which features a collection of 30 stocks and has a proven history of comfortably outperforming its benchmark that incorporates all three — the S&P 500, S&P mid-cap, and Russell 2000 indices. Why does this occur? Collectively, HQ Portfolio stocks have delivered superior returns with lower risk compared to the benchmark index; they present less volatility, as evidenced in HQ Portfolio performance metrics.
2025-10-31 13:16 6mo ago
2025-10-31 09:10 6mo ago
Netflix May Buy Warner Bros stocknewsapi
NFLX WBD
Instead of just making movies on its own, Netflix Inc. (NASDAQ: NFLX) may buy Warner Bros.
2025-10-31 13:16 6mo ago
2025-10-31 09:10 6mo ago
How Palantir Stock Might React To Earnings? stocknewsapi
PLTR
Palantir Technologies (NASDAQ:PLTR) is scheduled to announce its earnings on Monday, November 3, 2025. Growth is expected to be underpinned by accelerating adoption of its AI platform, rising enterprise demand, and deeper commercial partnerships that are broadening the company’s industry footprint. Continued strength in government contracts is also likely to drive performance.

The Palantir Technologies Inc (PLTR) stock is displayed on a mobile phone with Palantir in the background in this photo illustration in Brussels, Belgium, on August 6, 2025. (Photo by Jonathan Raa/NurPhoto via Getty Images)

NurPhoto via Getty Images

The firm currently has a market capitalization of $460 billion. Over the past twelve months, revenue was $3.4 billion, and the company reported operational profit with $570 million in operating profits and a net income of $763 million. While how the stock reacts after the earnings report will depend on how the results and future outlook compare to investor expectations, analyzing past results can be beneficial if you are a trader focused on events.

This can be done in two ways: either comprehend the historical probabilities and prepare yourself ahead of the earnings announcement, or assess the relationship between immediate and medium-term returns following earnings and make an investment one day after the announcement.

View earnings reaction history of all stocks

Investing in a single stock can be risky, but adopting a wider, diversified strategy as we do with the Trefis High Quality Portfolio provides significant value. Additionally, think about what the long-term performance of your portfolio could be if you allocated 10% to commodities, 10% to gold, and 2% to crypto alongside equities.

Palantir Technologies' Historical Chances of Positive Post-Earnings Return

Here are some insights into one-day (1D) returns following earnings:

Over the past five years, 20 earnings data points have been recorded, with 11 showing positive and 9 showing negative one-day (1D) returns. Overall, positive 1D returns were observed about 55% of the time.This percentage notably rises to 67% if we analyze data from the last 3 years instead of 5.The median of the 11 positive returns = 20%, while the median of the 9 negative returns = -13%More data about the observed 5-Day (5D) and 21-Day (21D) returns post earnings is summarized along with the statistics in the table below.

Returns

Trefis

Relationship Between 1D, 5D, and 21D Historical Returns

A relatively less risky approach (though ineffective if the correlation is weak) is to understand the relationship between short-term and medium-term returns after earnings, identify a pair with the strongest correlation, and execute the appropriate trade. For instance, if 1D and 5D exhibit the highest correlation, a trader could position themselves “long” for the next 5 days following a positive 1D post-earnings return. Below is some correlation data based on a 5-year and a 3-year (more recent) history. Please note that the correlation 1D_5D refers to the link between 1D post-earnings returns and the following 5D returns.

Relationship Between Returns

Trefis

If you’re looking for potential upside with a smoother experience than investing in a single stock like PLTR, consider the Trefis High Quality (HQ) Portfolio. This collection of 30 stocks has a history of successfully outperforming its benchmark, which includes the three—S&P 500, S&P mid-cap, and Russell 2000 indices. What accounts for this? Collectively, HQ Portfolio stocks have yielded superior returns with reduced risk compared to the benchmark index, creating a smoother investment journey, as demonstrated by HQ Portfolio performance metrics.
2025-10-31 13:16 6mo ago
2025-10-31 09:10 6mo ago
Buy The Dip In CMG Stock? stocknewsapi
CMG
SAN DIEGO, CALIFORNIA - AUGUST 2: A Chipotle logo is displayed outside their restaurant on August 2, 2025 in San Diego, California. (Photo by Kevin Carter/Getty Images)

Getty Images

Chipotle Mexican Grill stock (NYSE: CMG) crashed 18% yesterday, October 30, 2025, after the company reported its Q3 2025 earnings.

For the third time this year, Chipotle cut its sales forecast due to weaker-than-expected comparable sales. Management attributed this disappointing performance to persistent macroeconomic pressures and a notable pullback in spending from its core customers, particularly the 25-to-35 age group.

This single-day drop has extended CMG’s recent decline to 23.2% in under a month (falling from $42.36 on 10/21/2025 to a current price of $32.53). Given this sharp correction, the central question for investors is: Should you buy this dip? Buying a stock after a decline is a valid strategy, provided the company is a quality business with a history of bouncing back.

It turns out that CMG stock meets basic quality criteria, having generated a median return of 94% over one year, and a peak return of 102% after experiencing sharp declines (>30% in 30 days) historically. For a brief overview, CMG offers fast-casual Mexican food with around 3,000 locations in the United States, Canada, the United Kingdom, France, Germany, and other parts of Europe since 1993.

For insights regarding stock fundamentals and evaluations: Read Buy or Sell Chipotle Mexican Grill Stock to gain a comprehensive view.

That being said, if you seek an upside with less volatility than holding an individual stock like CMG, consider the High Quality Portfolio. It has comfortably outperformed its benchmark—a combination of the S&P 500, Russell, and S&P MidCap indexes—and has achieved returns exceeding 105% since its inception. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.

Historical Median Returns Post DipsHistorical Median Returns Post Dips

Trefis

Historical Dip-Wise DetailsCMG has experienced 2 occurrences since 1/1/2010 when the dip threshold of -30% within 30 days was breached

102% median peak return within 1 year of dip occurrence350 days is the median duration to peak return following a dip-19% median maximum drawdown within 1 year of dip eventHistorical Dip-Wise Details

Trefis

Chipotle Mexican Grill Passes Basic Financial Quality ChecksIt is essential to assess revenue growth, profitability, cash flow, and the strength of the balance sheet to mitigate the risk that a dip may signal a deteriorating business situation.

CMG Basic Financial Quality Checks

Trefis

Investing in a single stock without comprehensive analysis can be risky. Consider the Trefis Reinforced Value (RV) Portfolio, which has outperformed its all-cap stocks benchmark (combination of the S&P 500, S&P mid-cap, and Russell 2000 benchmark indices) to produce strong returns for investors. Why is that? The quarterly rebalanced mix of large-, mid-, and small-cap RV Portfolio stocks provided a responsive way to make the most of upbeat market conditions while limiting losses when markets head south, as detailed in RV Portfolio performance metrics.
2025-10-31 13:16 6mo ago
2025-10-31 09:10 6mo ago
Charter Communications (CHTR) Q3 Earnings and Revenues Lag Estimates stocknewsapi
CHTR
Charter Communications (CHTR - Free Report) came out with quarterly earnings of $8.34 per share, missing the Zacks Consensus Estimate of $9.32 per share. This compares to earnings of $8.82 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of -10.52%. A quarter ago, it was expected that this cable provider would post earnings of $10.05 per share when it actually produced earnings of $9.18, delivering a surprise of -8.66%.

Over the last four quarters, the company has surpassed consensus EPS estimates just once.

Charter, which belongs to the Zacks Cable Television industry, posted revenues of $13.67 billion for the quarter ended September 2025, missing the Zacks Consensus Estimate by 0.52%. This compares to year-ago revenues of $13.8 billion. The company has topped consensus revenue estimates three times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Charter shares have lost about 32.6% since the beginning of the year versus the S&P 500's gain of 16%.

What's Next for Charter?While Charter has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Charter was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $10.72 on $13.9 billion in revenues for the coming quarter and $37.20 on $55.15 billion in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Cable Television is currently in the bottom 31% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

Another stock from the same industry, WideOpenWest (WOW - Free Report) , has yet to report results for the quarter ended September 2025.

This cable TV company is expected to post quarterly loss of $0.20 per share in its upcoming report, which represents a year-over-year change of +25.9%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.

WideOpenWest's revenues are expected to be $140.7 million, down 11% from the year-ago quarter.
2025-10-31 13:16 6mo ago
2025-10-31 09:10 6mo ago
WisdomTree, Inc. (WT) Q3 Earnings and Revenues Top Estimates stocknewsapi
WT
WisdomTree, Inc. (WT - Free Report) came out with quarterly earnings of $0.23 per share, beating the Zacks Consensus Estimate of $0.21 per share. This compares to earnings of $0.18 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of +9.52%. A quarter ago, it was expected that this company would post earnings of $0.18 per share when it actually produced earnings of $0.18, delivering no surprise.

Over the last four quarters, the company has surpassed consensus EPS estimates just once.

WisdomTree, Inc., which belongs to the Zacks Financial - Miscellaneous Services industry, posted revenues of $125.62 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 1.50%. This compares to year-ago revenues of $113.17 million. The company has topped consensus revenue estimates just once over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

WisdomTree, Inc. shares have added about 10.3% since the beginning of the year versus the S&P 500's gain of 16%.

What's Next for WisdomTree, Inc.?While WisdomTree, Inc. has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for WisdomTree, Inc. was favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #2 (Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.22 on $133.96 million in revenues for the coming quarter and $0.77 on $478.43 million in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Financial - Miscellaneous Services is currently in the top 34% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

One other stock from the same industry, Brookfield Asset Management (BAM - Free Report) , is yet to report results for the quarter ended September 2025. The results are expected to be released on November 7.

This investment manager is expected to post quarterly earnings of $0.40 per share in its upcoming report, which represents a year-over-year change of +5.3%. The consensus EPS estimate for the quarter has been revised 3.5% lower over the last 30 days to the current level.

Brookfield Asset Management's revenues are expected to be $1.33 billion, up 9.9% from the year-ago quarter.
2025-10-31 13:16 6mo ago
2025-10-31 09:10 6mo ago
Piper Sandler Companies (PIPR) Q3 Earnings and Revenues Surpass Estimates stocknewsapi
PIPR
Piper Sandler Companies (PIPR - Free Report) came out with quarterly earnings of $3.82 per share, beating the Zacks Consensus Estimate of $2.96 per share. This compares to earnings of $2.57 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of +29.05%. A quarter ago, it was expected that this company would post earnings of $1.99 per share when it actually produced earnings of $2.95, delivering a surprise of +48.24%.

Over the last four quarters, the company has surpassed consensus EPS estimates four times.

Piper Sandler Companies, which belongs to the Zacks Financial - Investment Bank industry, posted revenues of $455.31 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 12.09%. This compares to year-ago revenues of $359.57 million. The company has topped consensus revenue estimates four times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Piper Sandler Companies shares have added about 9.1% since the beginning of the year versus the S&P 500's gain of 16%.

What's Next for Piper Sandler Companies?While Piper Sandler Companies has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Piper Sandler Companies was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $3.84 on $464.24 million in revenues for the coming quarter and $13.84 on $1.66 billion in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Financial - Investment Bank is currently in the top 14% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

Another stock from the same industry, MarketAxess (MKTX - Free Report) , has yet to report results for the quarter ended September 2025. The results are expected to be released on November 7.

This operator of bond trading platforms is expected to post quarterly earnings of $1.69 per share in its upcoming report, which represents a year-over-year change of -11.1%. The consensus EPS estimate for the quarter has been revised 6.5% lower over the last 30 days to the current level.

MarketAxess' revenues are expected to be $206.42 million, down 0.1% from the year-ago quarter.
2025-10-31 13:16 6mo ago
2025-10-31 09:10 6mo ago
LyondellBasell's Earnings and Revenues Beat Estimates in Q3 stocknewsapi
LYB
Key Takeaways LyondellBasell posted adjusted EPS of $1.01, topping estimates but down from $1.91 a year ago.Improved U.S. olefins margins and higher polyethylene demand aided performance.LYB expects seasonal softness and higher feedstock costs to pressure Q4 results.
LyondellBasell Industries N.V. (LYB - Free Report) recorded a loss of $890 million or $2.77 per share. This compares unfavorably with a profit of $573 million or $1.75 per share reported a year ago.

Barring one-time items, LYB posted adjusted earnings of $1.01 per share, down from the year-ago quarter's figure of $1.91. It topped the Zacks Consensus Estimate of 80 cents.

The company’s net sales in the reported quarter were $7,727 million, which beat the Zacks Consensus Estimate of $7,493.9 million. Net sales fell around 10% from $8,604 million in the prior-year quarter.

LYB saw improved profitability in the Olefins & Polyolefins — Americas segment, backed by higher olefins margins and increased sales volumes. Sales volumes were supported by higher domestic demand for polyethylene.

LyondellBasell’s Segment HighlightsIn the reported quarter, the Olefins & Polyolefins — Americas segment's revenues declined around 13% year over year to $2,606 million. The figure beat the consensus estimate of $2,531 million.

Similarly, Olefins & Polyolefins — Europe, Asia, the international segment revenues declined 8% year over year to $2,587 million. It topped the consensus estimate of $2,293 million.

In the Intermediates and Derivatives segment sales were $2,343 million, a decline of roughly 13% year over year, beating the consensus estimate of $2,325 million.

The Advanced Polymer Solutions revenues were $870 million, representing a decline of around 3% year over year, missing the consensus estimate of $891 million.

The Technology segment's revenues were $115 million, marking a decline of roughly 21%, and lagging the consensus estimate of $137 million.

LYB’s FinancialsLYB generated $983 million in cash from its operating activities in the reported quarter. The company continued its balanced capital allocation strategy by spending $406 million on capital expenditures and distributing $443 million to shareholders via dividends and share buybacks. At the end of the quarter, LYB had $1.8 billion in cash and cash equivalents, along with $6.5 billion in total available liquidity.

LYB’s OutlookIn the fourth quarter, LyondellBasell anticipates reduced operating rates and year-end seasonality to impact results across most of its businesses. Increased natural gas and feedstock costs are expected to put pressure on integrated polyolefins margins in North America. LYB also sees soft industrial and consumer demand to persist in Europe. While Industry downtime aided oxyfuels margins during October, seasonally higher costs for feedstocks and reduced octane values are expected to pressure margins for the balance of the fourth quarter. Cost reduction initiatives are also forecast to offset some of the pricing pressures in Advanced Polymer Solutions.

LYB remains on track with its Cash Improvement Plan, which is expected to deliver on a $600 million target for 2025 and at least $1.1 billion by the end of next year.

LYB’s Price PerformanceShares of LyondellBasell have lost 47.8% in the past year compared with the Zacks Chemicals Diversified industry’s 27.4% decline.

Image Source: Zacks Investment Research

LYB’s Zacks Rank & Key PicksLYB currently carries a Zacks Rank #5 (Strong Sell).

Some better-ranked stocks worth a look in the basic materials space are Avino Silver & Gold Mines Ltd. (ASM - Free Report) , Royal Gold, Inc. (RGLD - Free Report) and and Fortuna Mining Corp. (FSM - Free Report) .

Avino Silver is slated to report third-quarter results on Nov. 6. The Zacks Consensus Estimate for third-quarter earnings is pegged at 3 cents per share. ASM’s earnings beat the Zacks Consensus Estimate in each of the last four quarters, with the average surprise being 141.7%. Avino Silver carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Royal Gold is scheduled to report third-quarter results on Nov. 5. The Zacks Consensus Estimate for RGLD’s third-quarter earnings is pegged at $2.30 per share. RGLD’s earnings beat the Zacks Consensus Estimate in each of the last four quarters, with the average surprise being 8.9%. Royal Gold currently sports a Zacks Rank #1.

Fortuna Mining is scheduled to report third-quarter results on Nov. 5. FSM carries a Zacks Rank #2 at present. Fortuna Mining’s earnings beat the consensus estimate in one of the last four quarters and missed thrice.
2025-10-31 13:16 6mo ago
2025-10-31 09:14 6mo ago
Advisory: CAE's FY2026 Q2 financial results conference call stocknewsapi
CAE
, /PRNewswire/ - (NYSE: CAE) (TSX: CAE) – CAE will release its second quarter financial results on Tuesday, November 11, 2025, after market close. Analysts and institutional investors are invited to attend a conference call on Wednesday, November 12, at 8:00 a.m. Eastern Time (ET) during which a review of CAE's performance and outlook will be provided.

Calin Rovinescu, Executive Chairman of the Board, Matthew Bromberg, President and Chief Executive Officer, Nick Leontidis, Chief Operating Officer, Constantino Malatesta, Interim Chief Financial Officer and Andrew Arnovitz, Senior Vice President, Investor Relations and Enterprise Risk Management will participate in this call intended for financial analysts and institutional investors.  

The conference call will be available via a live audio webcast and a recording will be available following the event at  www.cae.com/investors/. It will also be possible to attend by telephone in North America by dialing 1-800-990-2777. 

International Toll-Free Access 
International participants who wish to join the call should click on this link, select the flag of the country where their phone number is registered, complete the form and press the button to submit. They will immediately receive a call on the number provided and will be joined to the conference on a muted line. Afterwards, press *1 to join the question queue.

About CAE

At CAE, we exist to make the world safer. We deliver cutting-edge training, simulation, and critical operations solutions to prepare aviation professionals and defence forces for the moments that matter. Every day, we empower pilots, cabin crew, maintenance technicians, airlines, business aviation operators, and defence and security personnel to perform at their best and when the stakes are the highest. Around the globe, we're everywhere customers need us to be, with approximately 13,000 employees at around 240 sites and training locations in over 40 countries. For nearly 80 years, CAE has been at the forefront of innovation, consistently seeking to set the standard by delivering excellence in high-fidelity flight simulators and training solutions, while embedding sustainability at the heart of everything we do. By harnessing technology and enhancing human performance, we strive to be the trusted partner in advancing safety and mission readiness - today and tomorrow.

Read our FY25 Global Annual Activity and Sustainability Report.

CAE Contacts: 
General Media
Samantha Golinski, Vice President, Public Affairs & Global Communications,
+1 438-805-5856, [email protected] 

Investor Relations
Andrew Arnovitz, Senior Vice President, Investor Relations and Enterprise Risk Management, +1-514-734-5760, [email protected]

SOURCE CAE Inc.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In
2025-10-31 12:16 6mo ago
2025-10-31 08:00 6mo ago
GRAINGER REPORTS RESULTS FOR THE THIRD QUARTER 2025 stocknewsapi
GWW
Continued execution fueling solid performance;
Company narrows full year 2025 earnings outlook

Third Quarter Highlights

Delivered sales of $4.7 billion, up 6.1%, or 5.4% on a daily, constant currency basis
Achieved operating margin of 11.0% on a reported basis, down 460 basis points, or 15.2% on an adjusted basis, down 40 basis points, which excludes the non-cash loss related to the Company's intended exit of the U.K. market, including the planned divestiture of Cromwell
Generated diluted EPS of $6.12 on a reported basis, down 38.0%, or $10.21 on an adjusted basis, up 3.4%
Produced $597 million in operating cash flow and returned $399 million to Grainger shareholders through dividends and share repurchases
Updating full year 2025 guidance, including a narrowed adjusted diluted EPS range of $39.00 to $39.75

, /PRNewswire/ -- Grainger (NYSE: GWW) today reported results for the third quarter of 2025 with sales of $4.7 billion, up 6.1%, or 5.4% on a daily, constant currency basis, and adjusted diluted EPS of $10.21, up 3.4% compared to the third quarter of 2024. 

"We delivered results in-line with our expectations for the quarter, reinforcing the value and differentiated experience Grainger consistently creates for our customers," said D.G. Macpherson, Chairman and CEO. "Looking ahead, we remain focused on navigating the continued uncertain environment through strong execution, industry-leading service and innovative capabilities to deliver on what matters most to our stakeholders."

2025 Third Quarter Financial Summary

($ in millions, except per share amounts)

Q3 2025

Q3 2024

Q3'25 vs. Q3'24

Fav. / (Unfav.)

Reported

Adjusted(1)

Reported

Adjusted

Reported

Adjusted

Net Sales

$4,657

$4,657

$4,388

$4,388

6.1 %

6.1 %

Gross Profit

$1,798

$1,798

$1,720

$1,720

4.5 %

4.5 %

Operating Earnings

$511

$707

$686

$686

(25.5) %

3.1 %

Net Earnings Attributable to W.W. Grainger, Inc.

$294

$490

$486

$486

(39.5) %

0.8 %

Diluted Earnings Per Share

$6.12

$10.21

$9.87

$9.87

(38.0) %

3.4 %

Gross Profit Margin

38.6 %

38.6 %

39.2 %

39.2 %

(60) bps

(60) bps

Operating Margin

11.0 %

15.2 %

15.6 %

15.6 %

(460) bps

(40) bps

Effective Tax Rate

34.7 %

24.8 %

24.8 %

24.8 %

(990) bps

0 bps

(1) Reflects the asset impairment loss and other expenses recorded in the third quarter of 2025 related to the Company's intention to exit the U.K. market, including the planned divestiture of the Cromwell business, which was held for sale as of September 30, 2025. See the supplemental information of this release for further information regarding the Company's non-GAAP measures including reconciliations to the most directly comparable GAAP measure.

Revenue
Sales in the quarter increased 6.1% compared to the third quarter of 2024. When normalizing for the impact of foreign currency exchange, sales on a daily, constant currency basis increased 5.4% compared to the third quarter of 2024.

In the High-Touch Solutions - N.A. segment, sales were up 3.4% on both a daily and constant currency basis compared to the third quarter of 2024. Results for the segment were driven by volume growth and improving price contribution as tariff costs are passed. In the Endless Assortment segment, sales were up 18.2%, or 14.6% on a daily, constant currency basis, compared to the third quarter of 2024. Growth for the segment was driven by strong performance at both MonotaRO and Zoro.

Gross Profit Margin
Gross profit margin was 38.6% in the third quarter of 2025, a decrease of 60 basis points from the third quarter of 2024. 

In the High-Touch Solutions - N.A. segment, gross profit margin was 41.1%, a 50 basis point decrease compared to the prior year quarter as tariff-related inflation caused unfavorable price / cost timing and last-in, first-out (LIFO) inventory valuation headwinds. In the Endless Assortment segment, gross profit margin increased by 60 basis points from the third quarter of 2024 due to improvement across the segment.

Earnings
For the third quarter of 2025, total Company reported operating earnings were $511 million, down 25.5% compared to the third quarter of 2024. Reported operating margin was 11.0%, a 460 basis point decrease compared to the third quarter of 2024. On an adjusted basis, operating earnings for the quarter were $707 million, up 3.1% compared to the third quarter of 2024.  Adjusted operating margin was 15.2%, a 40 basis point decrease compared to the third quarter of 2024. This decrease in adjusted operating margin was driven by unfavorable gross margin in High-Touch Solutions - N.A., which was partially offset by expense leverage in Endless Assortment. These adjusted results for the quarter exclude the asset impairment loss from the planned divestiture of the Cromwell business, along with other expenses related to the intended exit from the U.K. market incurred in the current year period.

Diluted earnings per share for the third quarter of 2025 were $6.12 on a reported basis, down 38.0% compared to the third quarter of 2024. On an adjusted basis, diluted EPS was $10.21, up 3.4% compared to the third quarter of 2024. The increase was driven primarily by sales growth and fewer shares outstanding.

Tax Rate
For the third quarter of 2025, the effective tax rate was 34.7%, compared to 24.8% in the third quarter of 2024. The increase in the effective tax rate was primarily due to the loss from the planned divestiture of the Cromwell business and intended exit from the U.K. market, for which there are no corresponding tax benefits. On an adjusted basis, the effective tax rate was 24.8% in both periods.

Cash Flow
During the third quarter of 2025, the Company generated $597 million of cash flow from operating activities. The Company invested $258 million in capital expenditures, resulting in free cash flow of $339 million. During the quarter, the Company returned $399 million to Grainger shareholders through dividends and share repurchases.

Guidance
The Company is updating the following guidance ranges which include certain known tariff impacts.

Total Company(1)

Previous 2025 Guidance Range

(as of August 1, 2025)

Updated 2025 Guidance Range

(as of October 31, 2025)

Net Sales

$17.9 - $18.2 billion

$17.8 - $18.0 billion

   Sales growth

4.4% - 5.9%

3.9% - 4.7%

   Daily, organic constant currency sales growth

4.5% - 6.0%

4.4% - 5.1%

Gross Profit Margin

38.6% - 38.9%

38.9% - 39.1%

Adjusted Operating Margin

14.7% - 15.1%

15.0% - 15.2%

Adjusted Diluted Earnings per Share

$38.50 - $40.25

$39.00 - $39.75

Operating Cash Flow

$2.05 - $2.25 billion

$2.10 - $2.20 billion

CapEx (cash basis)

$0.55 - $0.65 billion

$0.625 - $0.675 billion

Share Buyback

$1.05 - $1.15 billion

$1.05 - $1.15 billion

Effective Tax Rate

~23.8%

~23.8%

Segment Adjusted Operating Margin

High-Touch Solutions - N.A.

16.5% - 16.9%

16.9% - 17.0%

Endless Assortment

9.2% - 9.6%

9.2% - 9.5%

 (1)

Guidance provided is on an adjusted basis. Daily, organic constant currency sales growth is adjusted for the impact

of one less selling day in 2025 as compared to 2024 and excludes the sales of certain divested or closed businesses

in the comparable prior year period post date of divestiture or closure and changes in foreign currency exchange

rates. The Company does not reconcile forward-looking non-GAAP financial measures. For further details see the

supplemental information of this release.

Webcast
The Company will conduct a live conference call and webcast at 11:00 a.m. ET on Friday, October 31, 2025, to discuss the third quarter results. The event will be hosted by D.G. Macpherson, Chairman and CEO, and Deidra Merriwether, Senior Vice President and CFO, and can be accessed at invest.grainger.com. To access the conference call via phone, please send a request to [email protected]. For those unable to participate in the live event, a webcast replay will be available for 90 days at invest.grainger.com.

About Grainger
W.W. Grainger, Inc., is a leading broad line distributor with operations primarily in North America, Japan and the United Kingdom. At Grainger, We Keep the World Working® by serving more than 4.5 million customers worldwide with maintenance, repair and operating (MRO) products and value-added solutions delivered through innovative technology and deep customer expertise. Known for its commitment to service and purpose-driven culture, the Company reported 2024 revenue of $17.2 billion. For more information, visit www.grainger.com.  

Visit invest.grainger.com to view information about the Company, including a supplement regarding 2025 third quarter results and additional Company information.

Safe Harbor Statement
All statements in this communication, other than those relating to historical facts, are "forward-looking statements." Forward-looking statements can generally be identified by their use of terms such as "anticipate," "estimate," "believe," "expect," "could," "forecast," "may," "intend," "plan," "predict," "project," "will," or "would," and similar terms and phrases, including references to assumptions. Grainger cannot guarantee that any forward-looking statement will be realized and achievement of future results is subject to risks and uncertainties, many of which are beyond Grainger's control, which could cause Grainger's results to differ materially from those that are presented. Forward-looking statements include, but are not limited to, statements about future strategic plans and future financial and operating results. Important factors that could cause actual results to differ materially from those presented or implied in the forward-looking statements include, without limitation: inflation, higher product costs or other expenses, including operational and administrative expenses; a major loss of customers; loss or disruption of sources of supply; changes in customer or product mix; increased competitive pricing pressures; changes in third-party practices regarding digital advertising; failure to enter into or sustain contractual arrangements on a satisfactory basis with group purchasing organizations; failure to develop, manage or implement new technology initiatives or business strategies including with respect to Grainger's eCommerce platforms and artificial intelligence; failure to adequately protect intellectual property or successfully defend against infringement claims; fluctuations or declines in Grainger's gross profit margin; Grainger's responses to market pressures; the outcome of pending and future litigation or governmental or regulatory proceedings, including with respect to wage and hour, anti-bribery and corruption, environmental, regulations related to advertising, marketing and the internet, consumer protection, pricing (including disaster or emergency declaration pricing statutes), product liability, compliance or safety, trade and export compliance, general commercial disputes, or privacy and cybersecurity matters; investigations, inquiries, audits and changes in laws and regulations; failure to comply with laws, regulations and standards, including new or stricter environmental laws or regulations; government contract matters; the impact of any government shutdown; disruption or breaches of information technology or data security systems involving Grainger or third parties on which Grainger depends; general industry, economic, market or political conditions; general global economic conditions, including existing, new, or increased tariffs, trade issues and changes in trade policies, inflation, and interest rates; currency exchange rate fluctuations; market volatility, including price and trading volume volatility or price declines of Grainger's common stock; commodity price volatility; facilities disruptions or shutdowns; higher fuel costs or disruptions in transportation services; effects of outbreaks of pandemic disease or viral contagions, global conflicts, natural or human induced disasters, extreme weather, and other catastrophes or conditions; effects of climate change; failure to execute on our efforts and programs related to environmental, social and governance matters; competition for, or failure to attract, retain, train, motivate and develop executives and key team members; loss of key members of management or key team members; loss of operational flexibility and potential for work stoppages or slowdowns if team members unionize or join a collective bargaining arrangement; changes in effective tax rates; changes in credit ratings or outlook; Grainger's incurrence of indebtedness or failure to comply with restrictions and obligations under its debt agreements and instruments and other factors that can be found in our filings with the Securities and Exchange Commission, including our most recent periodic reports filed on Form 10-K and Form 10-Q, which are available on our Investor Relations website. Forward-looking statements are given only as of the date of this communication and we disclaim any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. 

W.W. Grainger, Inc. and Subsidiaries

CONDENSED CONSOLIDATED STATEMENTS OF EARNINGS

(In millions of dollars, except for share and per share amounts)

(Unaudited)

Three Months Ended

September 30,

Nine Months Ended

September 30,

2025

2024

2025

2024

Net sales

$     4,657

$     4,388

$   13,517

$   12,935

Cost of goods sold

2,859

2,668

8,254

7,853

Gross profit

1,798

1,720

5,263

5,082

Selling, general and administrative expenses

1,287

1,034

3,402

3,078

Operating earnings

511

686

1,861

2,004

Other (income) expense:

Interest expense – net

20

19

61

60

Other – net

(1)

(4)

(10)

(18)

Total other expense – net

19

15

51

42

Earnings before income taxes

492

671

1,810

1,962

Income tax provision

171

166

481

470

Net earnings

321

505

1,329

1,492

Less net earnings attributable to noncontrolling interest

27

19

74

58

Net earnings attributable to W.W. Grainger, Inc.

$        294

$        486

$     1,255

$     1,434

Earnings per share:

Basic

$       6.13

$       9.90

$     26.02

$     29.10

Diluted

$       6.12

$       9.87

$     25.97

$     29.00

Weighted average number of shares outstanding:

Basic

47.8

48.8

48.0

49.0

Diluted

47.9

48.9

48.1

49.2

W.W. Grainger, Inc. and Subsidiaries

CONDENSED CONSOLIDATED BALANCE SHEETS

(In millions of dollars)

(Unaudited)

As of

(Unaudited)

Assets

September 30, 2025

December 31, 2024

Current assets

Cash and cash equivalents

$                                 535

$                              1,036

Accounts receivable (less allowance for credit

losses of $36 and $32, respectively)

2,408

2,232

Inventories – net

2,275

2,306

Prepaid expenses and other current assets

206

163

Assets held for sale

50



Total current assets

5,474

5,737

Property, buildings and equipment – net

2,237

1,927

Goodwill

361

355

Intangibles – net

264

243

Operating lease right-of-use

320

371

Other assets

192

196

Total assets

$                              8,848

$                              8,829

Liabilities and Shareholders' Equity

Current liabilities

Current maturities

$                                     2

$                                 499

Trade accounts payable

1,123

952

Accrued compensation and benefits

297

324

Operating lease liability

76

78

Accrued expenses

410

407

Income taxes payable

25

45

Liabilities held for sale

82



Total current liabilities

2,015

2,305

Long-term debt

2,367

2,279

Long-term operating lease liability

275

327

Deferred income taxes and tax uncertainties

135

101

Other non-current liabilities

95

114

Shareholders' equity

3,961

3,703

Total liabilities and shareholders' equity

$                              8,848

$                              8,829

 W.W. Grainger, Inc. and Subsidiaries

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In millions of dollars)

(Unaudited)

Three Months Ended

September 30,

Nine Months Ended

September 30,

2025

2024

2025

2024

Cash flows from operating activities:

Net earnings

$         321

$         505

$      1,329

$      1,492

Adjustments to reconcile net earnings to net cash

provided by operating activities:

Provision for credit losses

7

6

20

18

Deferred income taxes and tax uncertainties

36

9

37

24

Depreciation and amortization

65

59

190

175

Non-cash lease expense

21

20

62

61

Impairment loss and net losses from business

divestitures

196



196



Stock-based compensation

14

14

49

48

Change in operating assets and liabilities:

Accounts receivable

(40)

22

(252)

(183)

Inventories

(8)

15

(27)

86

Prepaid expenses and other assets

1

16

(32)

(26)

Trade accounts payable

(46)

(85)

185

99

Operating lease liabilities

(26)

(26)

(79)

(73)

Accrued liabilities

64

54

4

36

Income taxes – net

(5)

(2)

(42)

(64)

Other non-current liabilities

(3)

4

(20)

(10)

Net cash provided by operating activities

597

611

1,620

1,683

Cash flows from investing activities:

Capital expenditures

(258)

(88)

(558)

(283)

Proceeds from sale of assets



1

4

2

Other – net

(2)

2

11

19

Net cash used in investing activities

(260)

(85)

(543)

(262)

Cash flows from financing activities:

Proceeds from debt

27

500

90

503

Payments of debt



(21)

(503)

(38)

Proceeds from stock options exercised



16

2

26

Payments for employee taxes withheld from stock awards

(1)

(4)

(31)

(44)

Purchases of treasury stock

(291)

(227)

(798)

(739)

Cash dividends paid

(133)

(115)

(358)

(321)

Other – net



(1)

(1)

(2)

Net cash used in financing activities

(398)

148

(1,599)

(615)

Exchange rate effect on cash and cash equivalents

(1)

5

21

(18)

Net change in cash and cash equivalents

(62)

679

(501)

788

Cash and cash equivalents at beginning of period

597

769

1,036

660

Cash and cash equivalents at end of period

$         535

$      1,448

$         535

$      1,448

SUPPLEMENTAL INFORMATION - RECONCILIATION OF GAAP TO NON-GAAP
FINANCIAL MEASURES (Unaudited)

The Company supplements the reporting of financial information determined under U.S. generally accepted accounting principles (GAAP) with the non-GAAP financial measures as defined below. The Company believes these non-GAAP financial measures provide meaningful information to assist investors in understanding financial results and assessing future performance as they provide a better baseline for analyzing the ongoing performance of its business by excluding items that may not be indicative of core operating results.

Basis of presentation
The Company has a controlling ownership interest in MonotaRO, which is part of our Endless Assortment segment. MonotaRO's results are fully consolidated, reflected in U.S. GAAP, and reported one-month in arrears. Results will differ from MonotaRO's externally reported financials which follow Japanese GAAP.

Adjusted gross profit, adjusted SG&A, adjusted operating earnings, adjusted operating margin, adjusted net earnings, adjusted diluted EPS
Exclude certain non-recurring items, like restructuring charges, asset impairments, gains and losses associated with business divestitures and other non-recurring, infrequent or unusual gains and losses (together referred to as "non-GAAP adjustments"), from the Company's most directly comparable reported U.S. GAAP figures (reported gross profit, SG&A, operating earnings, net earnings and EPS). The Company believes these non-GAAP adjustments provide meaningful information to assist investors in understanding financial results and assessing future performance as they provide a better baseline for analyzing the ongoing performance of its business by excluding items that may not be indicative of core operating results.

Free cash flow (FCF) 
Calculated using total cash provided by operating activities less capital expenditures. The Company believes the presentation of FCF allows investors to evaluate the capacity of the Company's operations to generate free cash flow.

Daily sales 
Refers to sales for the period divided by the number of U.S. selling days for the period.

Daily, constant currency sales
Refers to daily sales adjusted for changes in foreign currency exchange rates.

Daily, organic constant currency sales
Refers to daily sales excluding the sales of certain divested or closed businesses in the comparable prior year period post date of divestiture or closure and changes in foreign currency exchange rates.

Foreign currency exchange
Calculated by dividing current period local currency daily sales by current period average exchange rate and subtracting the current period local currency daily sales divided by the prior period average exchange rate.

U.S. selling days:
2024: Q1-64, Q2-64, Q3-64, Q4-64, FY-256
2025: Q1-63, Q2-64, Q3-64, Q4-64, FY-255
2026: Q1-63, Q2-64, Q3-64, Q4-64, FY-255

As non-GAAP financial measures are not standardized, it may not be possible to compare these measures with other companies' non-GAAP measures having the same or similar names. These non-GAAP measures should not be considered in isolation or as a substitute for reported results. These non-GAAP measures reflect an additional way of viewing aspects of operations that, when viewed with GAAP results, provide a more complete understanding of the business. This press release also includes certain non-GAAP forward-looking information. The Company believes that a quantitative reconciliation of such forward-looking information to the most comparable financial measure calculated and presented in accordance with GAAP cannot be made available without unreasonable efforts. A reconciliation of these non-GAAP financial measures would require the Company to predict the timing and likelihood of future restructurings, asset impairments, and other charges. Neither of these forward-looking measures, nor their probable significance, can be quantified with a reasonable degree of accuracy. Accordingly, a reconciliation of the most directly comparable forward-looking GAAP measures is not provided.

The reconciliations provided below reconcile GAAP financial measures to non-GAAP financial measures used in this release: daily sales; daily, constant currency sales; and free cash flow.

Sales growth for the three months ended September 30, 2025

(percent change compared to prior year period)

(unaudited)

Q3 2025

Total Company

High-Touch Solutions - N.A.

Endless Assortment

Reported sales

6.1 %

3.4 %

18.2 %

Daily impact

— %

— %

— %

Daily sales(1)

6.1 %

3.4 %

18.2 %

Foreign currency exchange(2)

(0.7) %

— %

(3.6) %

Daily, constant currency sales

5.4 %

3.4 %

14.6 %

(1) Based on U.S. selling days, there was 64 selling days in Q3 2025 and Q3 2024.

(2) Excludes the impact of year-over-year foreign currency exchange rate fluctuations.

Free cash flow (FCF) for the three months ended September 30, 2025

(in millions of dollars)

(unaudited)

Q3 2025

Net cash flows provided by operating activities                                   

$                                                  597

Capital expenditures

(258)

Free cash flow

$                                                  339

Income statement adjustments  for the three months ended September 30, 2025 and 2024

(in millions of dollars)

(unaudited)

Q3 2025

Reported

Adjusted (2)  

Reported

Adjusted

Reported

Adjustment(1)

Adjusted

% of Net sales

Y/Y

Earnings reconciliation:

SG&A

$     1,287

$              (196)

$    1,091

27.6 %

23.4 %

24.5 %

5.5 %

Operating earnings

511

196

707

11.0

15.2

(25.5)

3.1

Other expense — net

(19)



(19)

0.4

0.4

26.7

26.7

Earnings before income

taxes

492

196

688

10.6

14.8

(26.7)

2.5

Income tax provision(3)

(171)



(171)

3.7

3.7

3.0

3.0

Net earnings

321

196

517

6.9

11.1

(36.4)

2.4

Noncontrolling interest(4)

(27)



(27)

0.6

0.6

42.1

42.1

Net earnings attributable

to W.W. Grainger, Inc.

$       294

$               196

$       490

6.3 %

10.5 %

(39.5) %

0.8 %

Diluted earnings per share:

$      6.12

4.09

$    10.21

(38.0) %

3.4 %

Q3 2024

Reported

Adjusted (2)  

Reported

Adjusted

Reported

Adjustment(1)

Adjusted

% of Net sales

Y/Y

Earnings reconciliation:

SG&A

$     1,034

$                  —

$    1,034

23.6 %

23.6 %

4.7 %

4.7 %

Operating earnings

686



686

15.6

15.6

2.8

2.8

Other expense — net

(15)



(15)

0.3

0.3





Earnings before income

taxes

671



671

15.3

15.3

2.9

2.9

Income tax provision

(166)



(166)

3.8

3.8

4.4

4.4

Net earnings

505



505

11.5

11.5

2.4

2.4

Noncontrolling interest(4)

(19)



(19)

0.4

0.4

11.8

11.8

Net earnings attributable

to W.W. Grainger, Inc.

$       486

$                  —

$       486

11.1 %

11.1 %

2.1 %

2.1 %

Diluted earnings per share:

$      9.87



$      9.87

4.7 %

4.7 %

(1) Reflects the asset impairment loss and other expenses recorded in the third quarter of 2025 related to the Company's intention to exit the U.K. market,

     including the planned divestiture of the Cromwell business, which was held for sale as of September 30, 2025. There were no non-GAAP adjustments

     for three months ended September 30, 2024.

(2) Calculated on the basis of reported net sales for the third quarter of 2025 and 2024.

(3)  The Company's reported and adjusted effective tax rates were 34.7% and 24.8% for the third quarter of 2025, respectively.

(4) The Company has a controlling ownership interest in MonotaRO with the residual representing noncontrolling interest.

SOURCE W.W. Grainger, Inc.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In
2025-10-31 12:16 6mo ago
2025-10-31 08:00 6mo ago
Getty Images and Perplexity strike multi-year image partnership stocknewsapi
GETY
A Media Snippet accompanying this announcement is available by clicking on this link.

NEW YORK, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Getty Images (NYSE: GETY), a preeminent global visual content creator and marketplace, and Perplexity, have today announced a global multi-year licensing agreement covering display of images from Getty Images across Perplexity’s AI-powered search and discovery tools.

Integrated deep into the content creation and display workflows, and leveraging Getty Images’ API technology, this agreement provides Perplexity with access to high-quality and differentiated creative and editorial imagery to create a richer visual experience. In addition, Perplexity will be making improvements to how it displays imagery, including image credit with link to source, to better educate users on how to use licensed imagery legally.

“We are pleased to reach this agreement with Perplexity, which acknowledges the importance of properly attributed content and its value in enhancing AI-powered products,” said Nick Unsworth, Vice President Strategic Development at Getty Images. “Partnerships such as this support AI platforms to increase the quality and accuracy of information delivered to consumers, ultimately building a more engaging and reliable experience. This agreement paves the way for a productive and collaborative partnership between our companies, where we will work together to improve attribution of our contributors' work and Getty Images’ high-quality creative and editorial content will enhance Perplexity’s platform.”

“Attribution and accuracy are fundamental to how people should understand the world in an age of AI,” said Jessica Chan, Head of Content and Publisher Partnerships at Perplexity. “Getty Images shares our belief that the future of AI-powered discovery requires respecting the creators behind the content. Together, we're helping people discover answers through powerful visual storytelling while ensuring they always know where that content comes from and who created it.”

About Getty Images

Getty Images (NYSE: GETY) is a preeminent global visual content creator and marketplace that offers a full range of content solutions to meet the needs of any customer around the globe, no matter their size. Through its Getty Images, iStock and Unsplash brands, websites and APIs, Getty Images serves customers in almost every country in the world and is the first-place people turn to discover, purchase and share powerful visual content from the world’s best photographers and videographers. Getty Images works with almost 600,000 content creators and more than 355 content partners to deliver this powerful and comprehensive content. Each year Getty Images covers more than 160,000 news, sport and entertainment events providing depth and breadth of coverage that is unmatched. Getty Images maintains one of the largest and best privately-owned photographic archives in the world with millions of images dating back to the beginning of photography.

Through its best-in-class creative library and Custom Content solutions, Getty Images helps customers elevate their creativity and entire end-to-end creative process to find the right visual for any need. With the adoption and distribution of generative AI technologies and tools trained on permissioned content that include indemnification and perpetual, worldwide usage rights, Getty Images and iStock customers can use text to image generation to ideate and create commercially safe compelling visuals, further expanding Getty Images capabilities to deliver exactly what customers are looking for.

For company news and announcements, visit our Newsroom.

About Perplexity
Perplexity is an AI-powered answer engine that draws from credible sources in real time to accurately answer questions with in-line citations, perform deep research, and more. Founded in 2022, the company's mission is to serve the world's curiosity by bridging the gap between traditional search engines and AI-driven interfaces. Each week, Perplexity answers more than 150 million questions globally. Perplexity is available in the app store and online at https://www.perplexity.com.

Media Contact Getty Images:
Julia Holmes
[email protected]

Media Contact Perplexity:
Beejoli Shah
[email protected]
2025-10-31 12:16 6mo ago
2025-10-31 08:00 6mo ago
Abercrombie & Fitch Co. to Report Third Quarter 2025 Results on November 25, 2025 stocknewsapi
ANF
October 31, 2025 08:00 ET

 | Source:

Abercrombie & Fitch Management Co.

NEW ALBANY, Ohio, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Abercrombie & Fitch Co. (NYSE: ANF) will host its quarterly earnings conference call for all interested parties on Tuesday, November 25, 2025, at 8:30 a.m. ET. A press release detailing the company’s third quarter results is expected to be issued shortly after 7:30 a.m. ET.   In addition, a presentation of the third quarter results will be available on the company’s website at approximately 7:30 a.m. ET.

Conference Call:To access the conference call by phone, participants will need to register to obtain a dial-in phone number and an access code. Register for the call using this link.  Webcast:To listen to a live webcast of the call, please visit corporate.abercrombie.com/investors/news-and-events/events/ and click the link to the webcast.  Replay:A replay of the webcast will be available at corporate.abercrombie.com/investors shortly after the call ends and will be archived for one year. Further information is available at corporate.abercrombie.com. Important information may be disseminated initially or exclusively via the website: investors should consult the site to access this information.

About Abercrombie & Fitch Co.

Abercrombie & Fitch Co. (NYSE: ANF) is a global, digitally led omnichannel specialty retailer of apparel and accessories catering to kids through millennials with assortments curated for their specific lifestyle needs.

The company operates a family of brands, including Abercrombie brands and Hollister brands, each sharing a commitment to offer products of enduring quality and exceptional comfort that support global customers on their journey to being and becoming who they are. Abercrombie & Fitch Co. operates approximately 810 stores under these brands across North America, Europe, Asia and the Middle East, as well as the e-commerce sites abercrombie.com, abercrombiekids.com, and hollisterco.com.

Investor Contact: Media Contact:Mo Gupta Kate WagnerAbercrombie & Fitch Co. Abercrombie & Fitch Co.(614) 283-6751 (614) [email protected] [email protected]
2025-10-31 12:16 6mo ago
2025-10-31 08:00 6mo ago
Options Traders Are All Over This Struggling Chip Stock stocknewsapi
WOLF
One of the worst stocks on Wall Street that hardly anybody talked about yesterday was Wolfspeed Inc (NYSE:WOLF), which dropped 18.2% to close at $26.16. The chipmaker reported worse-than-expected fiscal first-quarter revenue, and also issued a dismal fiscal second-quarter revenue outlook. This marked the company's first  quarterly report since it filed for Chapter 11 bankruptcy on June 30, but options traders weren't buying it.

WOLF made an unusual appearance on Senior Quantitative Analyst Rocky White's list of equities that attracted the highest options volume over the past two weeks. In the last 10 days, 7,963,705 puts and a meager 18,103 calls exchanged hands. On Oct. 24, a block of 120,000 weekly 10/25 2.50-strike puts were sold to open, followed not far behind by the 1.50-strike in the same weekly series.

The stock obviously traded above the sold strikes. After reopening on Sept. 30 at $18, the shares charged as high as $36.53 by Oct. 9, though they have drifted lower since. 

Puts have been popular for some time.  At the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), WOLF sports a 50-day put/call volume ratio of 4.97.
2025-10-31 12:16 6mo ago
2025-10-31 08:00 6mo ago
Stellantis: A Potential Value Trap Rather Than An Undervalued Opportunity stocknewsapi
STLA
SummaryStellantis reported Q3 sales growth and slight U.S. market share gains, but fundamentals have deteriorated significantly.STLA faces cash burn, declining margins, and a major $13B U.S. investment, shifting from a net cash to net debt position.Despite top-line recovery, cash flow remains negative, and the investment thesis now relies solely on a risky turnaround scenario.I maintain a sell rating on STLA, viewing it as a potential value trap rather than an undervalued opportunity, preferring GM among peers.Analyst’s Disclosure:I/we have a beneficial long position in the shares of RACE either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You
2025-10-31 12:16 6mo ago
2025-10-31 08:01 6mo ago
DAYFORCE SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation into Price Adequacy of Dayforce, Inc. (NYSE: DAY) Shareholder Buyout - Does $70.00 Per Share Undervalue Dayforce Shares? stocknewsapi
DAY
PHILADELPHIA--(BUSINESS WIRE)--Kaskela Law LLC is actively investigating the fairness of the recently announced buyout of Dayforce Inc. (NYSE: DAY) shareholders to determine whether the buyout price undervalues the company's shares. Dayforce shareholders are strongly encouraged to contact the firm to discuss their legal rights and options with respect to this buyout proposal. Click here to receive information about your legal rights and options: https://kaskelalaw.com/case/dayforce/ On August 2.
2025-10-31 12:16 6mo ago
2025-10-31 08:01 6mo ago
Industrials ETF (XLI) Hits Fresh 52-Week High stocknewsapi
XLI
For investors seeking momentum, the Industrial Select Sector SPDR ETF (XLI - Free Report) is probably on the radar now. The fund just hit a 52-week high and is up 39.2% from its 52-week low price of $112.75 per share.

But are there more gains in store for this ETF? Let’s take a quick look at the fund and its near-term outlook to get a better sense of where it might head.

XLI in FocusThe underlying Industrial Select Sector Index includes companies from the following industries: industrial conglomerates; aerospace & defense; machinery; air freight & logistics; road & rail; commercial services & supplies; electrical equipment; construction & engineering; building products; airlines; and trading companies & distributors. The product charges 8 basis points (bps) in annual fees (See: All Industrials ETFs here).

Why the Move?By a 10-2 vote, the Federal Reserve recently cut interest rates by a quarter percentage point for the second consecutive meeting this year, bringing its benchmark rate down to a range of 3.75%–4.00% (per CNBC).

The decision, though taken amid limited economic data due to the ongoing government shutdown, reflects the central bank’s intention to bolster economic growth and strengthen the labor market.At the same time, hopes of easing U.S.–China trade tensions have lifted investor sentiment. Lower rates and the trade truce optimism are great for industrials ETFs like XLI.

More Gains Ahead?XLI may continue its strong performance in the near term, with a positive weighted alpha of 16.97 (as per Barchart.com), which suggests a further rally.
2025-10-31 12:16 6mo ago
2025-10-31 08:04 6mo ago
Nasdaq likely to take the lead as Amazon lifts Halloween spirits stocknewsapi
AMZN
8am: Futures in high spirits
US stock futures were mostly higher ahead of the open after earnings from Amazon lifted spirits after Thursday's losses due to uncertainty about the future policy of the Federal Reserve after its chair, Jerome Powell, suggested a cut in December, to follow this week’s, was not a foregone conclusion.

The Nasdaq was poised to take the lead, with futures suggesting a 1.3% gain. S&P 500 Futures rose 0.8%, while those for the Dow were 0.1%. 

Amazon's shares jumped over 12% in pre-market trading after it reported earnings that were better than expected, driven by surging demand for its cloud computing services. Revenue at Amazon Web Services (AWS) jumped 20% to $33 billion in the third quarter, continuing an evident trend in Microsoft and Google's earnings reports.  

“The e-commerce division may have by far the bigger public profile, but it’s the cloud services AWS division which is the real engine of Amazon’s growth, and it’s this which sparked the share price into life overnight," commented AJ Bell's Russ Mould.

“Demand for computing power linked to AI is showing no signs of letting up, and that is driving significant growth for AWS, with third-quarter numbers helping to ease fears that this business was losing ground to rival operators.

For other global markets, it's a mixed picture as the week and October draw to a close. 

The FTSE 100 fell 0.3% in morning trading in London, while Frankfurt's Dax has fallen 0.2% and the Paris CAC 40 is 0.1% off the pace. 

Tokyo's Nikkei 225 bucked the trend in Asia, closing over 2% higher, while the Hang Seng in Hong Kong fell 1.4% and Shanghai's SSE Composite ended 0.8% lower. The BSE Sensex in Mumbai fell 0.6% and Sydney's ASX 200 retraced earlier losses to end just a few points down. 

"European markets are on the back foot in early trade, with the FTSE 100 leading the declines as we close out a week that has seen major volatility from a plethora of key announcements," commented Scope Markets' Joshua Mahony. "Coming off the back of yesterday’s ECB rate pause, this morning saw the latest inflation release dominate as core CPI rose unexpectedly to 2.4%.
2025-10-31 12:16 6mo ago
2025-10-31 08:04 6mo ago
Bank sees Brazil find as potential game-changer for BP stocknewsapi
BP
Citi has reiterated its buy rating on BP PLC (LSE:BP.) after the company released more details about its Bumerangue oil discovery offshore Brazil, which the bank believes could prove transformational.

The discovery, first announced in July, lies in the Campos Basin and is now thought to contain several billion barrels of light oil and condensate, according to Citi’s interpretation of the new geological data.

The bank said BP’s latest technical disclosures support the view that Bumerangue could be a “multi-billion barrel liquids discovery,” with the potential to materially reshape the group’s upstream portfolio.

Crucially, BP holds 100% ownership of the block, giving it full control over development decisions and any future partnerships.

Citi described that combination of scale and equity as “a rare and highly attractive proposition” among current global discoveries.

While the bank cautioned that appraisal drilling and commercial testing will be needed to confirm recoverable volumes, it said the initial results reinforce BP’s strategy of focusing on higher-margin, lower-carbon barrels in regions with fiscal stability and existing infrastructure.

Citi kept its 'buy' rating and 475p price target, saying Bumerangue strengthens BP’s medium-term growth story at a time when investor sentiment toward traditional exploration remains subdued.
2025-10-31 12:16 6mo ago
2025-10-31 08:05 6mo ago
enVVeno Medical Reports Third Quarter 2025 Financial Results and Provides Corporate Update stocknewsapi
NVNO
- Cash and investments are sufficient to fund current operations through Q2 2027, not including VenoValve commercialization and the enVVe IDE study - Cash burn of $4.2 million in Q3 remains in line with projected quarterly range - Ongoing engagement with FDA for supervisory appeal of the VenoValve PMA decision with feedback expected by the end of 2025 IRVINE, CA / ACCESS Newswire / October 31, 2025 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno Medical" or the "Company"), a company setting new standards of care for the treatment of deep venous disease, today reported financial results for the third quarter 2025. Summary of Financial Results for the Third Quarter 2025 The Company ended the quarter with $31.0 million in cash and investments.
2025-10-31 12:16 6mo ago
2025-10-31 08:05 6mo ago
Kingstone Declares Quarterly Dividend stocknewsapi
KINS
KINGSTON, NEW YORK / ACCESS Newswire / October 31, 2025 / Kingstone Companies, Inc. (Nasdaq:KINS) (the "Company" or "Kingstone"), a Northeast regional property and casualty insurance holding company, today announced that its Board of Directors has declared a quarterly cash dividend of $0.05 per share of common stock. The Company will pay the dividend on November 26, 2025, to stockholders of record at the close of business on November 11, 2025.
2025-10-31 12:16 6mo ago
2025-10-31 08:05 6mo ago
Aemetis to Review Third Quarter 2025 Financial Results on November 6, 2025 stocknewsapi
AMTX
CUPERTINO, CA, Friday, October 31, 2025 – PRISM MediaWire (Press Release Service – Press Release Distribution) –  Aemetis, Inc. (NASDAQ: AMTX) announced that the company will host a conference call to review the release of its third quarter 2025 earnings report:

Date:   Thursday, November 6, 2025

Time:   11 am Pacific Time (PT)

Live Participant Dial In (Toll Free): +1-888-506-0062 entry code 188767 

Live Participant Dial In (International): +1-973-528-0011 entry code 188767

Webcast URL:  https://www.webcaster5.com/Webcast/Page/2211/53150

Attendees may submit questions during the Q&A (Questions & Answers) portion of the conference call.

The webcast will be available on the Company’s website (www.aemetis.com) under Investors/Conference Calls, along with the company presentation, recent announcements, and video recordings.

The voice recording will be available through November 13, 2025, by dialing (Toll Free) 877-481-4010 or (International) 919-882-2331 and entering conference ID number 53150. After November 13th, the webcast will be available on the Company’s website (www.aemetis.com) under Investors/Conference Calls.

About Aemetis

Headquartered in Cupertino, California, Aemetis is a renewable natural gas and renewable fuel company focused on the operation, acquisition, development, and commercialization of innovative technologies that lower fuel costs and reduce emissions. Founded in 2006, Aemetis is operating and actively expanding a California biogas digester network and pipeline system to convert dairy waste gas into Renewable Natural Gas. Aemetis owns and operates a 65 million gallon per year ethanol production facility in California’s Central Valley near Modesto that supplies about 80 dairies with animal feed. Aemetis owns and operates an 80 million gallon per year production facility on the East Coast of India producing high quality distilled biodiesel and refined glycerin. Aemetis is developing a sustainable aviation fuel and renewable diesel fuel biorefinery in California, renewable hydrogen, and hydroelectric power to produce low carbon intensity renewable jet and diesel fuel. For additional information about Aemetis, please visit www.aemetis.com. 

Investor Relations/

Media Contact:

Todd Waltz

(408) 213-0940

[email protected]

External Investor Relations

Contact:

Kirin Smith

PCG Advisory Group

(646) 863-6519

[email protected]

Source: Aemetis, Inc.
2025-10-31 12:16 6mo ago
2025-10-31 08:05 6mo ago
Portland General Electric (POR) Q3 Earnings Surpass Estimates stocknewsapi
POR
Portland General Electric (POR - Free Report) came out with quarterly earnings of $1 per share, beating the Zacks Consensus Estimate of $0.98 per share. This compares to earnings of $0.9 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of +2.04%. A quarter ago, it was expected that this electric utility would post earnings of $0.65 per share when it actually produced earnings of $0.66, delivering a surprise of +1.54%.

Over the last four quarters, the company has surpassed consensus EPS estimates three times.

Portland General Electric, which belongs to the Zacks Utility - Electric Power industry, posted revenues of $952 million for the quarter ended September 2025, missing the Zacks Consensus Estimate by 2.51%. This compares to year-ago revenues of $929 million. The company has topped consensus revenue estimates two times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Portland General Electric shares have added about 5% since the beginning of the year versus the S&P 500's gain of 16%.

What's Next for Portland General Electric?While Portland General Electric has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Portland General Electric was favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #2 (Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.71 on $892.8 million in revenues for the coming quarter and $3.22 on $3.6 billion in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Utility - Electric Power is currently in the top 24% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

Consolidated Edison (ED - Free Report) , another stock in the same industry, has yet to report results for the quarter ended September 2025. The results are expected to be released on November 6.

This utility is expected to post quarterly earnings of $1.76 per share in its upcoming report, which represents a year-over-year change of +4.8%. The consensus EPS estimate for the quarter has been revised 3.3% higher over the last 30 days to the current level.

Consolidated Edison's revenues are expected to be $4.16 billion, up 1.7% from the year-ago quarter.
2025-10-31 12:16 6mo ago
2025-10-31 08:05 6mo ago
Interface (TILE) Surpasses Q3 Earnings and Revenue Estimates stocknewsapi
TILE
Interface (TILE - Free Report) came out with quarterly earnings of $0.61 per share, beating the Zacks Consensus Estimate of $0.46 per share. This compares to earnings of $0.48 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of +32.61%. A quarter ago, it was expected that this carpet tile company would post earnings of $0.47 per share when it actually produced earnings of $0.6, delivering a surprise of +27.66%.

Over the last four quarters, the company has surpassed consensus EPS estimates four times.

Interface, which belongs to the Zacks Textile - Home Furnishing industry, posted revenues of $364.53 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 2.68%. This compares to year-ago revenues of $344.27 million. The company has topped consensus revenue estimates three times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Interface shares have added about 9.5% since the beginning of the year versus the S&P 500's gain of 16%.

What's Next for Interface?While Interface has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Interface was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.40 on $352 million in revenues for the coming quarter and $1.70 on $1.38 billion in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Textile - Home Furnishing is currently in the bottom 29% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

Another stock from the broader Zacks Consumer Discretionary sector, Cinemark Holdings (CNK - Free Report) , has yet to report results for the quarter ended September 2025. The results are expected to be released on November 5.

This movie theater owner is expected to post quarterly earnings of $0.46 per share in its upcoming report, which represents a year-over-year change of -61.3%. The consensus EPS estimate for the quarter has been revised 2% higher over the last 30 days to the current level.

Cinemark Holdings' revenues are expected to be $838.56 million, down 9% from the year-ago quarter.
2025-10-31 12:16 6mo ago
2025-10-31 08:05 6mo ago
Linde (LIN) Q3 Earnings and Revenues Top Estimates stocknewsapi
LIN
Linde (LIN - Free Report) came out with quarterly earnings of $4.21 per share, beating the Zacks Consensus Estimate of $4.18 per share. This compares to earnings of $3.94 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of +0.72%. A quarter ago, it was expected that this gas supplier would post earnings of $4.03 per share when it actually produced earnings of $4.09, delivering a surprise of +1.49%.

Over the last four quarters, the company has surpassed consensus EPS estimates four times.

Linde, which belongs to the Zacks Chemical - Specialty industry, posted revenues of $8.62 billion for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 0.17%. This compares to year-ago revenues of $8.36 billion. The company has topped consensus revenue estimates two times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Linde shares have added about 2.7% since the beginning of the year versus the S&P 500's gain of 16%.

What's Next for Linde?While Linde has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Linde was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $4.24 on $8.63 billion in revenues for the coming quarter and $16.46 on $33.84 billion in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Chemical - Specialty is currently in the bottom 39% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

Senestech, Inc. (SNES - Free Report) , another stock in the same industry, has yet to report results for the quarter ended September 2025.

This company is expected to post quarterly loss of $0.35 per share in its upcoming report, which represents a year-over-year change of +83.1%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.

Senestech, Inc.'s revenues are expected to be $0.73 million, up 52.1% from the year-ago quarter.
2025-10-31 12:16 6mo ago
2025-10-31 08:05 6mo ago
Magna (MGA) Beats Q3 Earnings and Revenue Estimates stocknewsapi
MGA
Magna (MGA - Free Report) came out with quarterly earnings of $1.33 per share, beating the Zacks Consensus Estimate of $1.24 per share. This compares to earnings of $1.28 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of +7.26%. A quarter ago, it was expected that this automotive supply company would post earnings of $1.19 per share when it actually produced earnings of $1.44, delivering a surprise of +21.01%.

Over the last four quarters, the company has surpassed consensus EPS estimates three times.

Magna, which belongs to the Zacks Automotive - Original Equipment industry, posted revenues of $10.06 billion for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 0.51%. This compares to year-ago revenues of $10.28 billion. The company has topped consensus revenue estimates four times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Magna shares have added about 6.8% since the beginning of the year versus the S&P 500's gain of 16%.

What's Next for Magna?While Magna has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Magna was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $1.63 on $10.46 billion in revenues for the coming quarter and $5.04 on $41.39 billion in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Automotive - Original Equipment is currently in the top 37% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

One other stock from the same industry, Luminar Technologies, Inc. (LAZR - Free Report) , is yet to report results for the quarter ended September 2025.

This company is expected to post quarterly loss of $1.08 per share in its upcoming report, which represents a year-over-year change of +55%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.

Luminar Technologies, Inc.'s revenues are expected to be $17.59 million, up 13.6% from the year-ago quarter.
2025-10-31 12:16 6mo ago
2025-10-31 08:06 6mo ago
NU Stock: U.S. Bank License May Be the Next Growth Catalyst stocknewsapi
NU
On Sept. 30, Nu Holdings Ltd. NYSE: NU announced that it had applied for a national bank license in the United States.
2025-10-31 12:16 6mo ago
2025-10-31 08:06 6mo ago
Orpea SA (ORRRY) Q3 2025 Sales Call Transcript stocknewsapi
ORPEF
Orpea SA (OTC:ORRRY) Q3 2025 Sales Call October 27, 2025 8:00 PM EDT

Company Participants

Jean-Marc Boursier - Deputy CEO & CFO
Samuel Henry-Diesbach

Conference Call Participants

Aleksander Peterc - Sanford C. Bernstein & Co., LLC., Research Division
Christophe-Raphael Ganet - ODDO BHF Corporate & Markets, Research Division
Laurent Gelebart - BNP Paribas, Research Division
David Cerdan - Kepler Cheuvreux, Research Division

Presentation

Operator

Good morning, and welcome to the emeis Q3 2025 Revenue Conference Call hosted by Mr. Jean-Marc Boursier, Group CFO; and Samuel Henry-Diesbach, Investor Relations Director.

The call will be structured in 2 parts. First, a presentation by the emeis Group management team, and afterwards there will be Q&A session. [Operator Instructions]

I will now hand over to the management team. Gentlemen, please go ahead.

Jean-Marc Boursier
Deputy CEO & CFO

Good morning to you, and thank you very much for attending this conference call related to our business activity and sales at the end of September 2025. I'm Jean-Marc Boursier. And before answering the question you may have with Samuel , I would like to share with you a few words about our activity and revenues.

Please also note that a dedicated presentation can be found on our website. As you may have already seen in the press release published this morning, the third quarter of the year is part of a continued improvement trend that began to take shape mid of 2024. This momentum is indeed continuing both in terms of occupancy rate and sales across all businesses and all geographies where we operate. This third quarter even shows encouraging signs, especially in Germany but also in our French clinics.

So first, regarding occupancy rates. The momentum continued to improve quarter after quarter. The group average occupancy rate now stands at 88% in the third quarter, up 1.8 points year-on-year and even

Recommended For You
2025-10-31 12:16 6mo ago
2025-10-31 08:07 6mo ago
Smithfield Foods Donates $150,000 to Food Banks in 22 States to Fight Hunger stocknewsapi
SFD
SMITHFIELD, Va., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Smithfield Foods donated $150,000 to 30 food banks in its 22-state operational footprint to support neighbors in local communities experiencing food insecurity.

“Smithfield believes in the power of community and the importance of supporting hunger relief,” said Jim Monroe, vice president of corporate affairs for Smithfield Foods. “This donation helps provide critical support to our neighbors facing hunger and reflects our continuing commitment to doing good in the places we call home.”

The recipient food banks include:

Colorado – Food Bank of the RockiesGeorgia – Atlanta Community Food BankIllinois – Northern Illinois Food BankIndiana – Gleaners and Food Finders Food BankIowa – Food Bank of Iowa and River Bend Food BankKansas – Kansas Food BankKentucky – God’s Pantry Food BankMaryland – Maryland Food BankMassachusetts – Food Bank of Western MassachusettsMinnesota – Second Harvest HeartlandMissouri – Second Harvest Community Food Bank, Harvesters – The Community Food Network, Food Bank for Central & Northeast Missouri, and Ozarks Food HarvestNebraska – Food Bank for the Heartland and Food Bank of LincolnNorth Carolina – Food Bank of Central & Eastern North Carolina and Second Harvest Food Bank of Southeast North CarolinaOhio – Freestore FoodbankOklahoma – Regional Food Bank of OklahomaPennsylvania – Westmoreland Food BankSouth Carolina – Harvest Hope Food BankSouth Dakota – Feeding South DakotaTennessee –Second Harvest Food Bank of Middle TennesseeUtah – Utah Food BankVirginia – Virginia Peninsula Foodbank and Foodbank of Southeastern Virginia and the Eastern ShoreWisconsin – Feeding America Eastern Wisconsin These donations are part of Smithfield’s long-standing commitment to fighting hunger and strengthening the communities where its employees live, work and raise their families.

Smithfield's hunger relief program, Helping Hungry Homes®, has provided hundreds of millions of servings of protein in all 50 U.S. states since 2008. Smithfield donated more than 25 million servings of protein, valued at nearly $28 million, to food banks, disaster relief efforts and community outreach programs across the U.S. in 2024. 

To learn more about Smithfield’s initiatives to strengthen local communities, visit smithfieldfoods.com/good-is-what-we-do.

About Smithfield Foods 
Smithfield Foods, Inc. (Nasdaq: SFD) is an American food company with a leading position in packaged meats and fresh pork products. With a diverse brand portfolio and strong relationships with U.S. farmers and customers, we responsibly meet demand for quality protein around the world.

Contact:

Ray Atkinson 
Smithfield Foods
(757) 576-1383 
[email protected]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/238348bb-62ae-4295-8859-4eef1e449f48
2025-10-31 12:16 6mo ago
2025-10-31 08:07 6mo ago
Blaqclouds Announces the Launch of Deploytokens.com — Multi-Chain Token Creation Powered by Apollo Wallet stocknewsapi
BCDS
Key Takeaways

Blaqclouds Launches DeployTokens Platform
Blaqclouds, Inc. (OTC: BCDS) introduced DeployTokens.com, a no-code token-generation platform that enables users to create, manage, and launch digital assets across 20+ EVM-compatible blockchains.
Seamless Multi-Chain & Apollo Wallet Integration
The platform integrates with ApolloWallet.io for direct on- and off-ramp functionality, enabling users to mint, distribute, and fund projects without centralized exchanges.
Empowering Web3 Creators & Businesses
DeployTokens supports token creation, NFT campaigns, DAO governance, vesting, and cross-chain liquidity tools—helping developers, creators, and enterprises scale Web3 adoption efficiently.

Robesonia, PA, October 31, 2025 – PRISM MediaWire (Press Release Service – Press Release Distribution) – Blaqclouds Inc. (OTC: BCDS), a leading Web3 infrastructure and blockchain technology company, today announced the official launch of DeployTokens.com, a powerful no-code token creation platform that enables users to design, deploy, and distribute tokens instantly across more than 20 major blockchains.

The platform represents a major advancement in Web3 accessibility — combining multi-chain deployment, smart-contract automation, and wallet-integrated minting through the Apollo Wallet, Blaqclouds’ flagship Web3 wallet solution.

Multi-Chain Tokenization Made Simple

DeployTokens.com eliminates the traditional barriers to creating blockchain tokens. Through a simple, no-code interface, users can launch customized tokens, execute bulk airdrops, or create community reward systems across an expansive suite of supported networks, including Ethereum (ETH), BNB Chain (BNB), Polygon (POLY), Ape Chain (APE), ZEUSx Chain (ZEUSX), and Olympus (OLYM) — with additional EVM chains integrated continuously.

Each token deployed on the platform is supported by verified smart contracts, ensuring security, transparency, and full compatibility with popular block explorers and DeFi protocols.

Powered by Apollo Wallet

At the heart of DeployTokens.com is its seamless integration with Apollo Wallet, providing users with secure, one-click token deployment, real-time transaction tracking, and cross-chain management. Through Apollo’s embedded on-ramp/off-ramp infrastructure, creators and businesses can move effortlessly between fiat and digital assets, making tokenization accessible to anyone — from emerging projects to enterprise developers.

Key Features

No-Code Token Launch: Deploy customizable tokens on 20+ chains in minutes.
Verified Smart Contracts: Automatically validated and explorer-ready code.
Bulk Token Distribution: Built-in multi-send and airdrop automation tools.
Cross-Chain Flexibility: Unified token management across EVM networks.
Wallet Integration: Secure, Apollo Wallet-powered creation and management.

“DeployTokens represents a major leap forward in Web3 accessibility and serves as a cornerstone of our Deploy Suite launch. By combining the power of the Apollo Wallet with multi-chain token deployment, we’re redefining how creators and businesses bring digital assets to market — making blockchain innovation faster, smarter, and easier for everyone. By integrating DeployToken.com with DeployLaunchpad.com, projects can now build their entire crypto ecosystem in minutes. The core of crypto is decentralization and utility, and with the Deploy Suite, projects can seamlessly connect to ZEUSxPay and ShopWithCrypto, giving their wallet holders instant real-world spendability. This marks the next evolution of growth in the digital asset sector.”

Shannon Hill, CEO of Blaqclouds Inc.
Deploy Launchpad is part of the Deploy Suite by Blaqclouds

Deploytokens.com

Deploylaunchpad.com  

yambit.com

About Blaqclouds, Inc.
Blaqclouds bridges traditional finance and decentralized ecosystems, building seamless, real-world blockchain applications that simplify commerce and payments. Its mission is to make spending crypto as easy, trusted, and usable as traditional currency.

Flagship consumer applications include:
– ShopWithCrypto.io – Crypto-to-gift card commerce
– ZEUSxPay.io – Web3 payments and merchant plugins
– DEX.ZEUSx.io – EVM-compatible decentralized exchange
– ApolloWallet.io – Secure, consumer-grade blockchain wallet

For a full list of platforms and solutions from Blaqclouds Nevada and Wyoming, visit: www.blaqclouds.io. For official Blaqclouds updates and information, please join https://www.thealley.io/group/blaqclouds-inc/discussion.

About DeployTokens

DeployTokens.com is a comprehensive, no-code token creation platform that empowers users to mint, distribute, and manage blockchain assets across 20+ networks. Designed for efficiency and security, DeployTokens is part of the growing Blaqclouds ecosystem — providing accessible tools for developers, creators, and enterprises building in the decentralized economy.

Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, which are intended to be covered by the safe harbors created thereby. Investors are cautioned that, all forward-looking statements involve risks and uncertainties, including without limitation, the ability of Blaqclouds, Inc. to accomplish its stated plan of business. Blaqclouds, Inc. believes that the assumptions underlying the forward-looking statements contained herein are reasonable, any of the assumptions could be inaccurate, and therefore, there can be no assurance that the forward-looking statements included in this press release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as a representation by Blaqclouds Inc. or any other person. This press release also contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve certain risks and uncertainties that may cause actual results to differ materially. Blaqclouds, Inc. assumes no obligation to update or revise any forward-looking statements.

Media Contact
Blaqclouds, Inc.
c/o www.theAlley.io
Email: [email protected]
Phone: 307-323-4430
Website: www.blaqclouds.io

Source: Blaqclouds, Inc.
2025-10-31 12:16 6mo ago
2025-10-31 08:11 6mo ago
Newell Brands (NWL) Misses Q3 Earnings and Revenue Estimates stocknewsapi
NWL
Newell Brands (NWL - Free Report) came out with quarterly earnings of $0.17 per share, missing the Zacks Consensus Estimate of $0.18 per share. This compares to earnings of $0.16 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of -5.56%. A quarter ago, it was expected that this consumer products company would post earnings of $0.24 per share when it actually produced earnings of $0.24, delivering no surprise.

Over the last four quarters, the company has surpassed consensus EPS estimates two times.

Newell Brands, which belongs to the Zacks Consumer Products - Staples industry, posted revenues of $1.81 billion for the quarter ended September 2025, missing the Zacks Consensus Estimate by 4.56%. This compares to year-ago revenues of $1.95 billion. The company has topped consensus revenue estimates just once over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Newell Brands shares have lost about 52.6% since the beginning of the year versus the S&P 500's gain of 16%.

What's Next for Newell Brands?While Newell Brands has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Newell Brands was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.26 on $1.98 billion in revenues for the coming quarter and $0.67 on $7.37 billion in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Consumer Products - Staples is currently in the bottom 17% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

National Vision (EYE - Free Report) , another stock in the same industry, has yet to report results for the quarter ended September 2025. The results are expected to be released on November 5.

This discount optical retailer and eye care provider is expected to post quarterly earnings of $0.12 per share in its upcoming report, which represents no change from the year-ago quarter. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.

National Vision's revenues are expected to be $474.55 million, up 5.1% from the year-ago quarter.
2025-10-31 12:16 6mo ago
2025-10-31 08:11 6mo ago
Proto Labs (PRLB) Tops Q3 Earnings and Revenue Estimates stocknewsapi
PRLB
Proto Labs (PRLB - Free Report) came out with quarterly earnings of $0.47 per share, beating the Zacks Consensus Estimate of $0.39 per share. This compares to earnings of $0.47 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of +20.51%. A quarter ago, it was expected that this custom parts manufacturer would post earnings of $0.33 per share when it actually produced earnings of $0.41, delivering a surprise of +24.24%.

Over the last four quarters, the company has surpassed consensus EPS estimates four times.

Proto Labs, which belongs to the Zacks Rubber - Plastics industry, posted revenues of $135.37 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 1.02%. This compares to year-ago revenues of $125.62 million. The company has topped consensus revenue estimates four times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Proto Labs shares have added about 35.7% since the beginning of the year versus the S&P 500's gain of 16%.

What's Next for Proto Labs?While Proto Labs has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Proto Labs was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.35 on $129.34 million in revenues for the coming quarter and $1.47 on $524.61 million in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Rubber - Plastics is currently in the bottom 11% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

One other stock from the same industry, Core Molding Technologies (CMT - Free Report) , is yet to report results for the quarter ended September 2025. The results are expected to be released on November 4.

This maker of fiber reinforced plastics is expected to post quarterly earnings of $0.40 per share in its upcoming report, which represents a year-over-year change of +11.1%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.

Core Molding Technologies' revenues are expected to be $70.36 million, down 3.6% from the year-ago quarter.
2025-10-31 12:16 6mo ago
2025-10-31 08:12 6mo ago
Johnson Fistel Continues Investigation on Behalf of FMC Corporation Long-Term Shareholders stocknewsapi
FMC
SAN DIEGO, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP, a leading stockholder rights law firm, continues an investigation into certain board members and executive officers of FMC Corporation (NYSE: FMC) for potential breaches of fiduciary duties and violations of the federal securities laws.

What is Johnson Fistel Investigating? Previously, a class action complaint was filed against the company alleging that Defendants made materially false and/or misleading statements and/or failed to disclose material adverse facts about the Company’s business, operations, and prospects throughout the Class Period. Specifically, Defendants failed to disclose that: (1) FMC’s channel management initiatives were not progressing as announced; (2) FMC, facing pricing pressure, decided to avoid sales opportunities rather than compete on pricing; and (3) as a result, FMC’s inventory in Latin America, Asia, Canada, and Eastern Europe became inflated.

Current stockholders who held their FMC stock before November 16, 2023, are encouraged to contact Johnson Fistel to discuss their legal rights in this matter. You can click or copy and paste the following link to join this investigation: https://www.johnsonfistel.com/investigations/fmc-corp/

About Johnson Fistel, PLLP:
Johnson Fistel, PLLP is a nationally recognized shareholder rights law firm with offices in California, New York, Georgia, Idaho, and Colorado. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. For more information about the firm and its attorneys, please visit http://www.johnsonfistel.com.

Attorney advertising.
Past results do not guarantee future outcomes.
Services may be performed by attorneys in any of our offices.

Johnson Fistel, PLLP has paid for the dissemination of this promotional communication, and Frank J. Johnson is the attorney responsible for its content.

Contact:
Johnson Fistel, PLLP
501 W. Broadway, Suite 800, San Diego, CA 92101
James Baker, Investor Relations or Frank J. Johnson, Esq., (619) 814-4471
[email protected] or [email protected]
2025-10-31 12:16 6mo ago
2025-10-31 08:13 6mo ago
CEF: I Remain Committed To The Gold And Silver Play stocknewsapi
CEF
SummarySprott Physical Gold and Silver Trust remains a buy due to its dual gold/silver exposure and current 5% discount to NAV.Gold's recent pullback presents a buying opportunity, supported by ongoing central bank accumulation, especially from emerging markets.A weakening USD and potential for accelerated Fed rate cuts create a favorable backdrop for both gold and silver prices, benefiting CEF. Guido Mieth/DigitalVision via Getty Images

Main Thesis & Background The purpose of this article is to evaluate the investment backdrop for precious metals - specific to gold and silver - and why I believe the Sprott Physical Gold and Silver Trust (CEF) is a

Analyst’s Disclosure:I/we have a beneficial long position in the shares of IAU, CEF either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You
2025-10-31 12:16 6mo ago
2025-10-31 08:15 6mo ago
Leatt Announces Date of Third Quarter 2025 Results Conference Call and Webcast stocknewsapi
LEAT
, /PRNewswire/ -- Leatt Corporation (OTCQB: LEAT), a leading developer and marketer of head-to-toe protective gear for a variety of sports, with an emphasis on extreme and high-velocity sports, announced today that it plans to release its financial results for the third quarter 2025 before the market opens on Thursday, November 6, 2025. The Leatt management team will host a conference call to discuss the Company's financial results on the same day at 10:00 am ET.

Conference Call:

Participants should dial in to the call ten minutes before the scheduled time, using the following numbers: 1-800-445-7795 (USA) or 1-785-424-1699 (international) to access the call.

Audio Webcast:

There will also be a simultaneous live webcast through the Company's website at www.leatt-corp.com. Participants should register on the website approximately ten minutes prior to the start of the webcast.

Replay:

An audio replay of the conference call will be available for seven days and can be accessed by dialing 1-844-512-2921 (USA) or 1-412-317-6671 (international). The replay passcode is 11160350.

For those unable to attend the call, a recording of the live webcast will be archived shortly following the event for 30 days on the Company's website.

About Leatt Corp

Driven by the science of thrill, Leatt Corporation develops head-to-toe personal protective gear for various sports, with a focus on mountain biking and extreme motorsports. This includes the award-winning Leatt-Brace®, a neck brace system considered the gold standard for neck protection when worn in conjunction with a helmet. Leatt products are designed for participants in extreme sports – more specifically - riding motorcycles, bicycles, mountain bikes, all-terrain vehicles, snowmobiles, and other open-air vehicles. For more information, visit www.leatt.com.

Follow Leatt® on Facebook, Twitter, and Instagram.

SOURCE Leatt Corporation

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In
2025-10-31 11:16 6mo ago
2025-10-31 07:00 6mo ago
Plurilock Announces Closing of $3 Million Strategic Investment stocknewsapi
PLCKF
October 31, 2025 7:00 AM EDT | Source: Plurilock Security Inc.
Vancouver, British Columbia--(Newsfile Corp. - October 31, 2025) - Plurilock Security Inc. (TSXV: PLUR) (OTCQB: PLCKF) ("Plurilock" or the "Company"), a global cybersecurity systems integrator, is pleased to announce that, further to its news release of October 17, 2025, the Company has closed its non-brokered private placement (the "Offering") of $3,000,000 through the issuance of 3,000 debenture units (the "Units") at $1,000 per Unit with a strategic investor.

Each Debenture Unit comprised of (i) $1,000 principal amount of 10% unsecured convertible debentures of the Company, convertible at the option of the holder at a price of $0.23 until October 30, 2028 (the "Debentures"), and (ii) 4,000 common share purchase warrants (the "Warrants") exercisable at a price of $0.25 until October 30, 2028, provided that if, any time following the date of issuance, the common shares of the Company (the "Shares") are listed on the New York Stock Exchange or NASDAQ (each, a "US Stock Exchange"), or the Company completes an indirect listing such that the Shares are exchanged for common shares of a public company trading on a US Stock Exchange, in which the holder may, at the Company's election, be given notice, by way of a news release, that the Warrants will expire 180 days following the date of such listing.

The Debentures bear interest at a rate of 10% per annum, payable in arrears every three months from the date of issue, in cash or Shares, or a combination thereof, at the election of the Company based on the 10-day VWAP at the time of the interest payment, subject to the policies of the TSX Venture Exchange (the "TSXV"). Interest shall be computed on the basis of a 360-day year composed of twelve 30-day months.

The Debentures cannot be converted into Shares and the Warrants cannot be exercised into Shares if it would result in the holder having a beneficial ownership of more than 9.99% of the issued and outstanding Shares.

The proceeds from the Offering will be used to accelerate Plurilock's growth initiatives, expand its Critical Services business, and strengthen working capital.

The Debenture Units are subject to final TSXV approval. All securities issued under the Offering are subject to a four-month and one-day statutory hold period from the date of issuance, in accordance with applicable securities laws.

The securities issued pursuant to the Offering have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act") or any U.S. state securities laws, and may not be offered or sold in the United States or to, or for the account or benefit of, United States persons absent registration or any applicable exemption from the registration requirements of the U.S. Securities Act and applicable U.S. state securities laws. This news release will not constitute an offer to sell or the solicitation of an offer to buy securities in the United States, nor will there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

Pursuant to the provisions of the Company's Amended Omnibus Incentive Plan, the Company has granted a total of 100,000 options to an officer of the Company at an exercise price of $0.23 per share for a period of five years, with 25% to vest one year from the grant date and 25% every 12 months thereafter. The Company has also granted a total of 1,750,000 restricted share units to certain directors, officers and consultants for a three-year term, with 1/3 to vest one year from the grant date and 1/3 every 12 months thereafter. These grants were made to appropriately reward the previous and ongoing contributions of the recipients and to encourage them to continue contributing significantly to Plurilock's success in future.

About Plurilock

Plurilock is a services-led, product-enabled, AI-native cybersecurity company that solves complex cyber problems in high-stakes environments where failure isn't an option. Trusted by Five-Eyes governments, NATO-aligned agencies, and Global 2000 enterprises, we defend critical infrastructure and safeguard the systems that power modern life. Our Critical Services division delivers operational resilience through unmatched expertise, proprietary IP, and AI-driven playbooks.

For more information, visit https://www.plurilock.com or contact:

Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the TSX Venture Exchange policies) accept responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This press release may contain certain forward-looking statements and forward-looking information (collectively, "forward-looking statements") related to future events or Plurilock's future business, operations, and financial performance and condition. Forward-looking statements normally contain words like "will", "intend", "anticipate", "could", "should", "may", "might", "expect", "estimate", "forecast", "plan", "potential", "project", "assume", "contemplate", "believe", "shall", "scheduled", and similar terms. Forward-looking statements are not guarantees of future performance, actions, or developments and are based on expectations, assumptions, and other factors that management currently believes are relevant, reasonable, and appropriate in the circumstances. Although management believes that the forward-looking statements herein are reasonable, actual results could be substantially different due to the risks and uncertainties associated with and inherent to Plurilock's business. Additional material risks and uncertainties applicable to the forward-looking statements herein include, without limitation, the impact of general economic conditions, and unforeseen events and developments. This list is not exhaustive of the factors that may affect the Company's forward-looking statements. Many of these factors are beyond the control of Plurilock. All forward-looking statements included in this press release are expressly qualified in their entirety by these cautionary statements. The forward-looking statements contained in this press release are made as at the date hereof, and Plurilock undertakes no obligation to update publicly or to revise any of the included forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required by applicable securities laws. Risks and uncertainties about the Company's business are more fully discussed under the heading "Risk Factors" in its most recent Annual Information Form. They are otherwise disclosed in its filings with securities regulatory authorities available on SEDAR+ at www.sedarplus.ca.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/272654
2025-10-31 11:16 6mo ago
2025-10-31 07:00 6mo ago
American Copper Development Corp. Announces Leadership Transition and Strategic Refocus stocknewsapi
ACDXF
October 31, 2025 7:00 AM EDT | Source: American Copper Development Corporation (Formerly Known as Cirrus Gold Corp.)
Vancouver, British Columbia--(Newsfile Corp. - October 31, 2025) - American Copper Development Corporation (CSE: ACDX) ("ACDX" or the "Company") announces a leadership transition.

Effective immediately, Anthony Paterson has been appointed Chief Executive Officer and Director, with Jeremy Ross and Ali Pickett joining the Board.

Mr. Anthony Paterson is an experienced venture builder and corporate strategist with a background in advancing exploration and development-stage companies. As an early strategic contributor to Prime Mining Corp., he currently serves as Lead Director of West Point Gold Corp. (TSXV: WPG) and Co-Founder of Patriot Critical Minerals Corp.

Mr. Jeremy Ross brings over twenty-five years of capital markets and corporate finance experience, having played key roles in several successful resource companies, including Prime Mining Corp., Fission Uranium Corp., Lithium Chile and American Lithium Corp.

Mr. Ali Pickett is a seasoned Chief Financial Officer and finance executive with over 17 years of experience spanning mining, biotechnology, and real estate. His expertise covers financial strategy, cross-border reporting, and capital markets transactions across multiple sectors.

The Company also announces the resignations of Daniel Schieber (CEO and Director), Stuart Ross, and Marcio Fonseca (Directors), effective October 30, 2025.

The new leadership team is undertaking a review of its assets, capital structure, and strategic priorities to refocus on value creation and disciplined execution.

About the Company

The Company is engaged in the business of mineral exploration and the acquisition of mineral property assets. Its objective is to locate and develop economic precious and base metal properties of merit and to conduct its exploration program on the Lordsburg Property.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

American Copper Development Corporation

For further information, please contact:‎
Anthony Paterson
Chief Executive Officer and Director
Phone: (778) 372-9888
Email: [email protected]

Cautionary Statement Regarding Forward-Looking Information

This news release includes certain "forward-looking ‎information" under applicable Canadian securities legislation, which include, but are limited to, statements relating to the use of proceeds from the Private Placement. ‎Forward-looking information involves risks, uncertainties, and other factors that could cause ‎actual results, performance, prospects, and opportunities to differ materially from those ‎expressed or implied by such forward-looking information. Forward-looking information is necessarily based on a number of estimates and ‎assumptions that, while considered reasonable, are subject to known and unknown risks, ‎uncertainties and other factors which may cause actual results and future events to differ ‎materially from those expressed or implied by such forward-looking information. ‎Accordingly, the forward-looking information discussed in this release, may not occur and ‎could differ materially as a result of these known and unknown risk factors and uncertainties ‎affecting ACDX. Although ACDX believes that the assumptions and factors used in ‎preparing the forward-looking information are reasonable, undue reliance should not be placed ‎on this information, which only applies as of the date of this news release, and no assurance can ‎be given that such events will occur in the disclosed time frames or at all. Except where ‎required by law, ACDX disclaims any intention or obligation to update or revise any forward-‎looking information, whether as a result of new information, future events, or otherwise.‎

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/272697
2025-10-31 11:16 6mo ago
2025-10-31 07:00 6mo ago
Transaction in Own Shares stocknewsapi
EDVMF
ENDEAVOUR ANNOUNCES TRANSACTION IN OWN SHARES

London, 31 October 2025 – Endeavour Mining plc (LSE:EDV, TSX:EDV) (“the Company”) announces it has purchased the following number of its ordinary shares of USD 0.01 each from Stifel Nicolaus Europe Limited.

Aggregated information

Dates of purchase:30 October 2025Aggregate number of ordinary shares of USD 0.01 each purchased:30,000Lowest price paid per share (GBp):                3,062.28Highest price paid per share (GBp):        3,062.28Volume weighted average price paid per share (GBp):        3,062.28 Following the cancellation of the repurchased shares, the Company will have no ordinary shares in treasury and 241,324,712 ordinary shares in issue. Therefore the total voting rights in the Company will be 241,324,712. This figure for the total number of voting rights may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA’s Disclosure Guidance and Transparency Rules.

These share purchases form part of the Company’s buy-back programme announced on 20 March 2025.

Transaction details

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 (the Market Abuse Regulation), the table below contains detailed information of the individual trades made by Stifel Nicolaus Europe Limited as part of the buyback programme.

Schedule of purchases

Shares purchased: Endeavour Mining plc (ISIN: GB00BL6K5J42)

Dates of purchases: 30 October 2025

Investment firm: Stifel Nicolaus Europe Limited

Individual transactions

Transaction date and timeVolumePrice (GBp)Trading Venue30 Oct 2025, 06:48 PM5,0003,062.28TSX* *56.3918CAD/share at CAD/GBP: 1.8415

CONTACT INFORMATION

For Investor Relations Enquiries:For Media Enquiries:Jack GarmanBrunswick Group LLP in LondonVice President of Investor RelationsCarole Cable, Partner+44 203 011 2723+ 44 207 404 [email protected]@brunswickgroup.com ABOUT ENDEAVOUR MINING PLC

Endeavour Mining is one of the world’s senior gold producers and the largest in West Africa, with operating assets across Senegal, Cote d’Ivoire and Burkina Faso and a strong portfolio of advanced development projects and exploration assets in the highly prospective Birimian Greenstone Belt across West Africa.

A member of the World Gold Council, Endeavour is committed to the principles of responsible mining and delivering sustainable value to its employees, stakeholders and the communities where it operates. Endeavour is admitted to listing and to trading on the London Stock Exchange and the Toronto Stock Exchange, under the symbol EDV.

For more information, please visit www.endeavourmining.com.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION

This news release contains "forward-looking statements" within the meaning of applicable securities laws.  All statements, other than statements of historical fact, are "forward-looking statements". Generally, these forward-looking statements can be identified by the use of forward-looking terminology such as "expects", "expected", "budgeted", "forecasts", and "anticipates".

Forward-looking statements, while based on management's best estimates and assumptions, are subject to risks and uncertainties that may cause actual results to be materially different from those expressed or implied by such forward-looking statements, including but not limited to: risks related to the successful integration of acquisitions; risks related to international operations; risks related to general economic conditions and credit availability, actual results of current exploration activities, unanticipated reclamation expenses; changes in project parameters as plans continue to be refined; fluctuations in prices of metals including gold; fluctuations in foreign currency exchange rates, increases in market prices of mining consumables, possible variations in ore reserves, grade or recovery rates; failure of plant, equipment or processes to operate as anticipated; accidents, labour disputes, title disputes, claims and limitations on insurance coverage and other risks of the mining industry; delays in the completion of development or construction activities, changes in national and local government regulation of mining operations, tax rules and regulations, and political and economic developments in countries in which Endeavour operates. Although Endeavour has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. Please refer to Endeavour's most recent Annual Information Form filed under its profile at www.sedarplus.ca for further information respecting the risks affecting Endeavour and its business.

Transaction in own shares
2025-10-31 11:16 6mo ago
2025-10-31 07:00 6mo ago
September 2025 Quarterly Activities Report stocknewsapi
RSRBF
QUEBEC CITY, Oct. 31, 2025 (GLOBE NEWSWIRE) -- West African gold producer and developer Robex Resources Inc. (“Robex” or the “Company”) (TSX-V: RBX | ASX: RXR | OTC: RSRBF | Börse Frankfurt: RB4) is pleased to report on its activities for the September 2025 Quarter. Robex owns the Nampala Gold Mine in Mali and continues to make strong progress on the construction of the Kiniero Gold Project in Guinea, which remains on schedule for first gold pour in Q4 CY25.

Highlights:

Robex and Predictive Discovery (ASX: PDI) announced a merger of equals, aiming to create a strengthened mid-tier West African gold producer. The merger, announced on 6 October 2025, is expected to close by early 2026, subject to satisfaction of closing conditions and shareholder approval.Robex accelerated the expiry of its 2024 warrants from 27 June 2026 to 18 October 2025 after the share price exceeded C$3.50 for 10 consecutive trading days. The Company raised C$148.2M, strengthening its balance sheet and highlighting strong investor confidence.Robex amended its US$130 million senior facility with Sprott, unlocking up to US$90 million to support Kiniero Gold Project development.Mining commenced on day and night shift at Kiniero, with delivery of ore to the run-of-mine (ROM) pad.Kiniero construction remains on schedule and on budget for first gold pour in Q4 2025. Mining is underway and more than 4.8 million LTI-free hours have been recorded. Major milestones have been achieved including near-complete mills, 45% electrical progress at the power station, 76% completion of the TSF, and full delivery of structural and electrical materials.Initiated 20,000m RC drilling at Sabali South (Kiniero) to expand resources, with diamond drilling planned at SGA and NEGD, while near-mine exploration continued at Nampala to extend mine life.Strategic planning advanced 2026 exploration programs, budgeting and target generation across Guinea and Mali.Nampala operation remains Lost Time Injury (LTI) free, with more than 2.04 million hours worked. Kiniéro project has recorded 4.86 million LTI-free hours.Nampala produced 9,774 ounces and sold 9,529 ounces of gold during the September 2025 quarter.Year-to-date gold production from Nampala totalled 34,401oz at an All-in Sustaining (AISC) of C$2,555/oz. Robex’s Managing Director and CEO Matt Wilcox commented:

“We advanced the Kiniero Gold Project strongly throughout the September quarter, with mining now underway and delivery of ore to the ROM pad, with drilling and blasting to commence shortly. Construction is progressing across all major areas, with no lost-time injuries reported during the quarter.

“Key milestones included major progress on the process plant, completion of critical concrete works, advancement of CIL tank installation, and continued work on the SAG mill and tailings storage facility. Site infrastructure, including power generation and fuel facilities, also progressed in line with schedule.

We remain committed to delivering Kiniero safely, efficiently, and responsibly, while maintaining strong engagement with host communities and stakeholders. Meanwhile, operations at the Nampala Gold Mine in Mali continued to perform despite challenging operating conditions.”

Kiniéro Gold Project, Guinea

Construction Overview

The Kiniero Project remains on track for first gold pour in Q4 2025, with construction and mine development advancing in line with schedule milestones.

Mining

Mining operations commenced during the quarter on both day and night shifts, with 82,590 tonnes of material mined, including 20,625 tonnes of ore and 10,000 tonnes of ore rehandled from historical stockpile to the main ROM pad.Initial mining activities have commenced with free-digging operations, and the first production blast being completed mid-October.Mining & ROM Pad management contracts services, Grade control contract services, Drill & Blast contract services and secondary haulage contract services all executed, and contractors have mobilised to site.

Figure 1: Aerial view of the Kiniéro site showing construction progress and ore stockpile on the ROM Pad

Process Plant and Infrastructure

Concrete work for the process plant and power station completed during the quarter, marking a major construction milestone.All platework, structural steel, piping, and electrical materials delivered to site.Structural, Mechanical & Piping (SMP) works are advancing, with structural steel erected or preassembled.SAG mill assembly is complete, with the mill floating on its bearing and the right gear installed; alignment and drivetrain installation are scheduled for early Q4 2025.Ball mill assembly is nearing completion, with ring gear installation to follow.Primary crushing and reclaim areas are well advanced, with steelwork and platework installation currently underway.Leaching circuit construction is ahead of schedule, with all intertank screens and agitators near complete on train A.Steelwork for the elution, gold room and reagent areas is progressing strongly. The onsite pipe fabrication workshop is fully operational, supporting accelerated progress in piping installation. Power Generation and Electrical Works

The power station construction remains on schedule, with low voltage motor control centres (MCCs) delivered and installed.Four engines (4MW) delivered to site, with based frame preparation underway and installation expected in October.Electrical work is advancing, with nearly 30,000m of cabling installed and the power station 45% electrically complete.Engine haul building structural steel completed, with cladding and ancillary works progressing.Fuel storage facility tankage erection progressed according to plan during the quarter. Tailing Storage Facility (TSF)

Construction of tailings storage facilities (TSF) is progressing on schedule.The eastern embankment is progressing strongly, with +500,000m3 of fill placed.Lining crew remobilized during last September, installing 78,650m2 of HDPE Liner.Earthworks for the tailing pipeline containment channel and process water pond completed and prepared for lining. Other Infrastructure

Overland HDPE piping, including the tailings and freshwater pipelines, advanced well with over 15km welded by quarter-end.Field-erected tankage reached 99% complete, with painting outstanding.Concrete contracting works completed, with contractor demobilization commencing in early October.ROM Haul roads and site access roads progressed, maintaining efficient material movement to the processing area. Construction Next Steps – Q4 2025

In the quarter ahead, Robex expects to:

Continue with SMP works for the process plant and power station.Complete mill installation.Continue with electrical and instrumentation installation in a staged approach to allow energization of switch rooms for commissioning in November.Complete the installation of four engines and commence commissioning and run on diesel by mid-November.Continue with tailings storage facility earthworks and lining.Complete mobilisation of operations, operation readiness and commissioning teams. Complete recruitment of operators and commence training programs.Continue with mining development works and ramp up mining with more ore delivered to the ROM pad.Continue grade control drilling at Sabali pit. Community Relations
During the quarter, Robex’s Kiniero project maintained strong engagement with host communities through the delivery of key social and community initiatives under the Company’s Corporate Social Responsibility (CSR) program:

Construction of four community centres in Ballan, Fara-Ballan, Mansounia, and Kiniero Centre were completed during the September quarter, with work having commenced in prior periods. Upgrades to the Ballan Primary School, including new facilities, were also finalised during the quarter.Improved local healthcare services through ambulance repairs at the Kiniero Health centre, donation of anti-venoms and installation of solar-powered equipment for vaccine storage.Supported education and community development, including the distribution of school kits to first-year students in nearby villages, and financial assistance for local cultural, religious, and sporting events.Maintained regular community engagement, with ongoing consultations held across projected-affected areas. Environmental and Safety Performance
At the in-development Kiniéro Project, Robex maintained strong environmental and health & safety practices during the quarter, reinforcing its commitment to responsible mining and early-stage community engagement. This proactive approach included:

Safety performance remained strong, with no lost time injuries (LTIs) recorded during the quarter.A new on-site ambulance was delivered, equipped with upgraded medical and emergency equipment to enhance first-response capability.The medical services contractor (AMS) mobilized in mid-September, including an expatriate emergency doctor and establishment of a dedicated emergency room.Construction of the new site clinic progressed and is expected to be completed by the end of October.The tree nursery program continued during the quarter, with extensive seeding underway to support future site rehabilitation and biodiversity enhancement.Contract for septic waste removal was finalised and waste management activities continued with the company’s waste removal contractor.Water samples were collected and sent for analysis at Sabali camp treatment plant to ensure continued compliance with environmental and health standards. Pre-Production Grade Control Completed at Sabali South

Robex has completed its pre-production grade control drilling campaign at Sabali South, ahead of planned mining activities at the deposit in Q4 2025. This follows the completion of the Mansounia grade control drilling program in Q2. The program comprised 2,843 inclined grade control drill holes, totalling 66,105 metres, aimed at refining subsurface grade definition in preparation for the commencement of mining. Grade control drilling results at Sabali south closely tracked the Mineral Reverse model. Results confirm the robustness of the geological model and support short-term mine planning.

September Quarter Progress at Kiniéro Gold Project, Guinea

Figure 2: Reclaim Chamber

Figure 3: Primary Crusher 

Figure 4: Milling & CIL Tank Train

Figure 5: CIL Tank Train A & B

Figure 6: Areial view of Kiniero site

Figure 7: Power Station

Nampala Gold Operation, Mali

 UnitsQ1 FY25Q2 FY25Q3 FY25 YTD FY25Financial Data             ProductionOz12,89211,7359,774 34,401SalesOz11,86913,1049,529 34,501Average Realised PriceC$/oz4,1604,5864,870 4,518       RevenueC$M49,37360,09946,406 155,878       Operating Data      Ore Minedt631,515720,924353,818 1,706,257Waste Minedt2,370,5691,964,1181,587,604 5,922,291Total Material Minedt3,002,0842,685,0421,941,442 7,628,548Stripping ratiow/o3.752.724.48 3.47Ore processedt559,013547,749501,300 1,608,062Head gradeg/t0.820.760.69 0.76Recovery%87.687.388.4 87.7               Material Mined: During the September 2025 quarter, total material mined amounted to 1,941,442 tonnes, comprising 1,587,604 tonnes of waste and 353,818 tonnes of ore. The strip ratio increased to 4.48, a 64.7% rise from 2.72 in the June 2025 quarter. This increase reflects a strategic focus on waste removal to facilitate access to deeper ore zones, which are expected to enhance both grade quality and ore availability in future periods.
Ore Processed: A total of 501,300 tonnes of ore were processed during the quarter, representing an 8.5% decrease from 547,749 tonnes in the June 2025 quarter. The reduced throughput was primarily due to limited ore availability, stemming from chute blockages, ore clogging caused by heavy rainfall, and electrical issues affecting instrumentation. Additional downtime for maintenance and crusher teeth replacement also contributed to the lower processing volumes.
Head Grade: The average head grade for the quarter was 0.69 g/t, down 10.2% (or 0.07 g/t) from 0.76 g/t in the previous quarter. This decline reflects the processing of an average-grade ore blend during the period. Despite the reduction, the grade remains aligned with the mine plan and grade control parameters.Recovery rate: Recovery improved to 88.4%, up 1.1% from 87.3% in the June quarter. This improvement was driven by enhanced control of high-grade rejects, which averaged 0.075 g/t compared to 0.092 g/t in the prior quarter. The improvement also reflects a lower proportion of transitional ore processed during the period.Gold Production: Gold production for the September 2025 quarter declined by 1,962 ounces to 9,774 ounces compared to the June quarter. The decrease was primarily due to lower mill throughput and a reduction in feed grade, which averaged 0.69 g/t versus 0.76 g/t in the June quarter. Environmental and Safety Performance

Safety performance remained strong, with no lost time injuries (LTIs) recorded during the quarter.No reportable environmental incidents or breaches recorded.Environmental monitoring programs continue for noise management, water and air quality Community and Social Responsibility
Robex continued to support local communities at the Nampala Mine during Q3 2025, reinforcing its commitment to sustainable development and community engagement. This included:

Contribution of ~C$353k to the local mining development fund.Support for education and training, including vocational programs for 32 young Malians and distribution of school supplies to students in nearby villages.Local partnerships and employment initiatives, including market garden purchases from women’s associations and engagement of community service providers through GIE Balimaya.Infrastructure improvements, including rehabilitation of the 36km N’Tjikouna-Nampala-Finkolo-Tiola road.Financial support for cultural, religious, and community events, including festivals and artistic biennials.Skills development and hydraulic training for 12 community members, plus provision of pump repair kits to local town halls.Extensive local procurement, supporting regional suppliers and strengthening economic opportunities in the Sikasso region. Exploration and Development
During the quarter, Robex made significant progress across its West African exploration portfolio, with key developments including:

Appointments

Exploration Leadership Appointments: A new Chief Exploration Officer, Mr. Justin Rivers commenced during the quarter, bringing extensive leadership and exploration expertise to the executive team. A Chief Exploration Geologist for Kiniero was also appointed, further strengthening in-country technical leadership.Structural Geology Specialist Engaged: consultant engaged to undertake comprehensive desktop and field-based structural mapping and interpretation of the Kiniero Gold Project in Guinea. The study aims to improve ore body understanding, specifically the structural controls on gold mineralisation, to guide planned exploration drilling and enhance deposit (Resource) Modelling. Kiniero Gold Project, Guinea

Reverse Circulation (RC) Drilling Program – Sabali South Deposit: A three-month RC drilling program commenced targeting depth extensions and infill opportunities in the central and northern portions of the Sabali South Deposit. The program comprises approximately 115 RC holes for ~20,000 metres, aiming to delineate an extensional indicated/inferred resource to support follow-up infill and conversion drilling activities planned for 2026.Diamond drilling program – SGA and NEGD Deposits: Final planning was completed for a diamond drilling campaign schedule to commence in October. The program will consist of 8 diamond holes for ~3,151 metres, targeting improve structural and lithological understanding at depth. The key objective is to define a potential maiden fresh rock inferred resource to support a conceptual underground mine planning study. Nampala Near-Mine Exploration, Mali

Near-mine exploration activities continued around the Nampala plant to evaluate sustaining, replacement and growth options, aiming to extend the mine’s life and enhance operational flexibility. CORPORATE

Sprott Facility

Robex maintains a US$130 million (C$177.9 million) senior secured facility with Sprott Resource Lending (US Manager) Corp. (“Sprott”) as agent and lead arranger, supporting construction of the Kiniero Gold Project and working capital requirements. The first drawdown of US$25 million (C$34 million) was completed in March 2025.

On 4 September 2025, Robex announced amendments to the Facility Agreement, providing enhanced funding flexibility. Under the revised terms, Robex now has access to US$90 million of the remaining facility without requiring the Mansounia Exploitation Permits or Mining Convention. This included an immediate US$30 million drawdown and US$60 million held in a Debt Proceeds Account, subject to standard release conditions. The remaining US$15m remains subject to receipt of the Mansounia mining permit and mining convention.

Capital Structure Update

The Company’s issued capital increase from 218,202,805 shares at 30 June 2025 to 244,079,269 at 30 September 2025. There shares are dual listed on the ASX (as CDIs) and the TSXV (as common shares).

Robex completed the acceleration of the expiry date for its listed common share purchase warrants issued on 27 June 2024, following ten consecutive trading days where the Company’s share price exceeded C$3.50 per share. As a result, the expiry date was advanced from 27 June 2026 to 18 October 2025:

During Q3, 25,876,464 warrants were exercised, generating gross proceeds of C$66.0 million.Between quarter-end and 18 October 2025, an additional 32,249,534 warrants were exercised, raising C$82.2 million.In total, from Q2 through to the end of the warrant exercise period, 58,125,998 warrants were exercised, resulting in gross proceeds of C$148.2 million.The remaining 130,006 warrants were not exercised and expired on 18 October 2025. FY25 GuidanceQ3 FY25YTD FY25 ForecastNampala Gold Operation    Gold Production9,774 Oz34,401 Oz 46,000 – 48,000 OzAll-in sustaining cost (AISC) (per ounce of gold sold)$2,555$2,318 <$2,400Sustaining capex$7,489$25,558 $30 - $34 millionStripping costs$6,736$22,184 $26 – $30 million           ASIC guidance has increased, driven by higher royalty payments resulting from elevated gold prices. Robex achieved a realised selling price of C$4,518/oz, significantly above the budgeted C$3,197/oz.

The Nampala mine remains on track to meet its full-year FY25 production guidance of 46,000 to 48,000 ounces, subject to the operational situation in Mali, including reliable access to fuel.

For FY25, sustaining capital expenditure is forecast to range between C$30–34 million, while stripping costs are estimated at C$26–30 million.

The following assumptions were used in preparing the 2025 forecast:

Average realized selling price for gold: C$3,197 per ounceFuel price: C$1.85 per litre$USD/$CAD exchange rate: 1.39 This announcement was approved and authorised for release by the Company’s Board of Directors.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Robex Resources Inc.
Matthew Wilcox, Managing Director and Chief Executive Officer
Alain William, Chief Financial Officer
Email: [email protected]
www.robexgold.com

Kiniéro Permit Area Details     Permit
NoTypeMineralArea (Km2)DepositCurrent Holding CompanyValidity/Status/Duration311Exploitation PermitGold95.51 SMGAwarded on 17 December 2020. Valid for a period of 15 years renewable on expiry310Exploitation PermitGold37.85 SMGAwarded on 17 December 2020. Valid for a period of 15 years renewable on expiry271Exploitation PermitGold99.35 SMGAwarded on 4 November 2020. Valid for a period of 15 years, renewable on expiry312Exploitation PermitGold93.63Sabali North and Central Sabali South, SGA, Jean and BanfareSMGAwarded on 17 December 2020. Valid for a period of 15 years, renewable on expiry        Mansounia Exploration Permit DetailsPermit
NoTypeMineralArea (Km2)DepositCurrent Holding CompanyStatus1048Exploration
PermitGold53.78MansouniaPenta GoldfieldsPermit awarded on 6 April 2020, valid for an initial period of 3 years and renewable on expiry. An exploitation permit application (to be issued in SMG’s name) was validly submitted to the CPDM in Q1 2023 for 50% of the Mansounia Permit Area. This application is still being processed, but the Company notes that on 7 March 2025 the Guinean Minister of Mines confirmed in writing that the application is complete and compliant.1049Exploration
PermitGold90.37MansouniaPenta
GoldfieldsPermit awarded on 6 April 2020, valid for an initial period of 3 years and renewable on expiry. An exploitation permit application (to be issued in SMG’s name) was validly submitted to the CPDM in Q1 2023 for 50% of the Mansounia Permit Area. This application is still being processed but the Company notes that on 7 March 2025 the Guinean Minister of Mines confirmed in writing that the application is complete and compliant.        Nampala Project Exploitation Permit DetailsPermit
CodePermit NameStart dateExpiry dateAreaStatusPE 2011/17Nampala exploitation permit
(permis D’exploitation de Nampala)21 March 201221 March 202416km2Active       Nampala Project Exploration Permit Details (South Mali)
   Permit
CodePermit NameStart dateAreaStatusPR: 17/868Kamasso19 September 2017100km2Under renewal processPR 16/802 Bis 1Diangounté28 November 201752km2Under renewal processPR:19/1038Sanoula28 August 201931.5km2Under renewal processPR: 19:/1039Mininko17 September 201946.20km2Under renewal processPR: 20/1088Gladié31 March 202152km2Under renewal process      Competent Person's Statement

Information in this Announcement that relates to exploration results is based on, and fairly represents, information and supporting documentation prepared by Mr. Amir Adeli, a Competent Person who is a Member of the Australian Institute of Mining and Metallurgy. Mr Adeli has sufficient experience that is relevant to the style of mineralisation and type of deposit under consideration and to the activity which he is undertaking to qualify as a ‘Competent Person’ as defined in the 2012 Edition of the ‘Australasian Code for Reporting of Exploration Results, Mineral Resources and Ore Reserves’ (JORC Code). Mr Adeli is an employee of Robex Resources Management Limited and consents to the inclusion in this announcement of all technical statements based on his information in the form and context in which it appears.

FORWARD-LOOKING INFORMATION AND FORWARD-LOOKING STATEMENTS

Certain information set forth in this news release contains “forward-looking statements” and “forward-looking information” within the meaning of applicable Canadian securities legislation (referred to herein as “forward-looking statements”). Forward-looking statements are included to provide information about the Company’s management’s (“Management’s”) current expectations and plans that allow investors and others to have a better understanding of the Company’s business plans and financial performance and condition.

Statements made in this news release that describe the Company’s or Management’s estimates, expectations, forecasts, objectives, predictions, projections of the future or strategies may be “forward-looking statements”, and can be identified by the use of the conditional or forward-looking terminology such as “aim”, “anticipate”, “assume”, “believe”, “can”, “contemplate”, “continue”, “could”, “estimate”, “expect”, “forecast”, “future”, “guidance”, “guide”, “indication”, “intend”, “intention”, “likely”, “may”, “might”, “objective”, “opportunity”, “outlook”, “plan”, “potential”, “should”, “strategy”, “target”, “will” or “would” or the negative thereof or other variations thereon. Forward-looking statements also include any other statements that do not refer to historical facts. In particular and without limitation, this news release contains forward-looking statements pertaining to the Facility Agreement, including the fulfilment of the conditions precedent thereunder, the ability of the Company to utilize any proceeds from the Initial Utilization, the ability of the Company to draw down on the Debt Facility for each Subsequent Utilization, the development of the Kiniero Gold Project and the issuance of Bonus Shares.

Forward-looking statements and forward-looking information are made based upon certain assumptions and other important factors that, if untrue, could cause the actual results, performance or achievements of the Company to be materially different from future results, performance or achievements expressed or implied by such statements or information. There can be no assurance that such statements or information will prove to be accurate. Such statements and information are based on numerous assumptions, including: the ability to execute the Company’s plans relating to the Kiniero Gold Project as set out in the feasibility study with respect thereto, as the same may be updated, the whole in accordance with the revised timeline previously disclosed by the Company; the Company’s ability to complete its planned exploration and development programs; the absence of adverse conditions at the Kiniero Gold Project; the absence of unforeseen operational delays; the absence of material delays in obtaining necessary permits; the price of gold remaining at levels that render the Kiniero Gold Project profitable; the Company’s ability to continue raising necessary capital to finance its operations; the ability of the Company to realize on the mineral resource and mineral reserve estimates; assumptions regarding present and future business strategies, local and global geopolitical and economic conditions and the environment in which the Company operates and will operate in the future; the Company’s ability to complete the listing of its common shares on the Australian Securities Exchange (ASX), and the anticipated timing of such listing; satisfaction of the conditions precedent under the Facility Agreement; the Borrower’s access to the facility made available under the Facility Agreement; and the utilisation of any amount received by the Borrower under the Facility Agreement for the purposes identified by the Company.

Certain important factors could cause the Company’s actual results, performance or achievements to differ materially from those in the forward-looking statements including, but not limited to: the risk that the Borrower is unable to fulfil the conditions precedent to drawdowns under the Facility Agreement, and is therefore not able to borrow some or all of the principal amount otherwise available under the Facility Agreement; the risk that the Company is unable to generate sufficient cash flow or complete subsequent debt or equity financings to allow it to repay amounts borrowed under the Facility Agreement; the risk that the obligors under the Facility Agreement are unable to comply with the financial and other covenants under the Facility Agreement, giving rise to an event of default; geopolitical risks and security challenges associated with its operations in West Africa, including the Company’s inability to assert its rights and the possibility of civil unrest and civil disobedience; fluctuations in the price of gold; uncertainties as to the Company’s estimates of mineral reserves and mineral resources; the speculative nature of mineral exploration and development; the replacement of the Company’s depleted mineral reserves; the Company’s limited number of projects; the risk that the Kiniero Gold Project will never reach the production stage (including due to a lack of financing); the Company’s capital requirements and access to funding; changes in legislation, regulations and accounting standards to which the Company is subject, including environmental, health and safety standards, and the impact of such legislation, regulations and standards on the Company’s activities; equity interests and royalty payments payable to third parties; price volatility and availability of commodities; instability in the global financial system; uncertainty surrounding the imposition of tariffs by one country, including, but not limited to, the United States, on goods or services being imported into that country from another country and the ultimate effect of such tariffs on the Company’s supply chains; the effects of high inflation, such as higher commodity prices; fluctuations in currency exchange rates, particularly as between the Canadian dollar, in which the Company presently raises its equity financings, and the US dollar; the risk of any pending or future litigation against the Company; limitations on transactions between the Company and its foreign subsidiaries; volatility in the market price of the Common Shares; tax risks, including changes in taxation laws or assessments on the Company; the Company obtaining and maintaining titles to property as well as the permits and licenses required for the Company’s ongoing operations; changes in project parameters and/or economic assessments as plans continue to be refined; the risk that actual costs may exceed estimated costs; geological, mining and exploration technical problems; failure of plant, equipment or processes to operate as anticipated; accidents, labour disputes and other risks of the mining industry; delays in obtaining governmental approvals or financing; the effects of public health crises on the Company’s activities; the Company’s relations with its employees and other stakeholders, including local governments and communities in the countries in which it operates; the risk of any violations of applicable anticorruption laws, export control regulations, economic sanction programs and related laws by the Company or its agents; the risk that the Company encounters conflicts with small-scale miners; competition with other mining companies; the Company’s dependence on third-party contractors; the Company’s reliance on key executives and highly skilled personnel; the Company’s access to adequate infrastructure; the risks associated with the Company’s potential liabilities regarding its tailings storage facilities; supply chain disruptions; hazards and risks normally associated with mineral exploration and gold mining development and production operations; problems related to weather and climate; the risk of information technology system failures and cybersecurity threats; the risk that the Company is not able to complete the listing of its common shares on the ASX within the anticipated timeframe or at all; the risk that the Borrower is not able to access the proceeds of the Debt Facility or use any amount received under the Facility Agreement for the purposes identified by the Company; and the risk that the Company may not be able to insure against all the potential risks associated with its operations.

Although the Company believes its expectations are based upon reasonable assumptions and has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. These factors are not intended to represent a complete and exhaustive list of the factors that could affect the Company; however, they should be considered carefully. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information.

The Company undertakes no obligation to update forward-looking information if circumstances or Management’s estimates, assumptions or opinions should change, except as required by applicable law. The reader is cautioned not to place undue reliance on forward-looking information.

The forward-looking information contained herein is presented for the purpose of assisting investors in understanding the Company’s expected financial and operational performance and results as at and for the periods ended on the dates presented in the Company’s plans and objectives, and may not be appropriate for other purposes.

See also the “Risk Factors” section of the Company’s Annual Information Form, available under the Company’s profile on SEDAR+ at www.sedarplus.ca or on the Company’s website at www.robexgold.com, for additional information on risk factors that could cause results to differ materially from forward-looking statements. All forward-looking statements contained in this news release are expressly qualified by this cautionary statement.

The Company has prepared this announcement based on information available to it. No representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions or conclusions contained in this announcement. To the maximum extent permitted by law, none of the Company, its directors, officers, employees, associates, advisers and agents, nor any other person accepts any liability, including, without limitation, any liability arising from fault or negligence on the part of any of them or any other person, for any loss arising from the use of this announcement or its contents or otherwise arising in connection with it.

This announcement is not an offer, invitation, solicitation, or other recommendation with respect to the subscription for, purchase or sale of any security, and neither this announcement nor anything in it shall form the basis of any contract or commitment whatsoever.

Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/80ff0721-f370-4529-bc2a-5d88b07f23f7
https://www.globenewswire.com/NewsRoom/AttachmentNg/28dab10f-28c3-440a-83a2-a4dc70e27cc5
https://www.globenewswire.com/NewsRoom/AttachmentNg/44d8a0d9-8b73-4571-979b-65ad183d3a81
https://www.globenewswire.com/NewsRoom/AttachmentNg/e50ce32c-7c9b-455b-9f88-02b36c77295e
https://www.globenewswire.com/NewsRoom/AttachmentNg/42fb5ec3-0321-4560-9a89-32f9ebdd1903
https://www.globenewswire.com/NewsRoom/AttachmentNg/8e9c492e-73c7-4924-834d-616186276d26
https://www.globenewswire.com/NewsRoom/AttachmentNg/04a2f16e-634b-43e3-b6ae-6597522bb0e0
2025-10-31 11:16 6mo ago
2025-10-31 07:00 6mo ago
Adagene Announces First Patient Dosed in Randomized Dose Optimization Cohort of the Phase 2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Microsatellite Stable Colorectal Cancer stocknewsapi
ADAG
October 31, 2025 07:00 ET

 | Source:

Adagene Inc.

Phase 2 clinical trial underway with first patient dosed in October to support a clear path to Phase 3 based on previous alignment with FDA

Patients randomized to either 10 or 20 mg/kg of muzastotug, in combination with KEYTRUDA with up to 30 patients per arm

Company anticipates trial completion in early 2027, and potential updates in 2026

Additional updates from the ongoing Phase 1b/2 trial with muzastotug, previously reported at ASCO 2025, are anticipated in the coming months

SAN DIEGO and SUZHOU, China, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced that the first patient has been dosed in its randomized, open label Phase 2 study of muzastotug in combination with Merck’s (known as MSD outside of the United States and Canada) anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) in patients with microsatellite stable colorectal cancer (MSS CRC) with no liver metastases. The Phase 2 primary endpoint is overall response rate (ORR).

“We are pleased that the randomized Phase 2 trial is now underway in order to confirm the preferred dose for Phase 3 in compliance with Project Optimus,” stated Peter Luo, Ph.D., CEO and President of R&D at Adagene. “To date, muzastotug has been safely dosed at 20 mg/kg Q6W, with less than 20% Grade 3 adverse events and no discontinuations, supporting its position as the potential best in class Treg depleting anti-CTLA-4 agent with improved therapeutic window. Our approach was further highlighted by the recent 2025 Nobel Prize in physiology awarded for the seminal discovery of regulatory T cells function, consistent with the MOA of muzastotug, leveraging CTLA-4 mediated intratumoral regulatory T cell depletion strategy to treat cancer. We look forward to sharing additional data from the ongoing Phase 1b/2 to provide further evidence that muzastotug’s improved safety profile allows for higher dosing and potentially better efficacy, which has precluded the use of first-generation anti-CTLA-4 therapies in this setting.”

As previously announced in July 2025, both the Phase 2 and Phase 3 trial designs and endpoints were confirmed following a meeting with the US Food and Drug Administration (FDA):

Patient Population: Future trials will enroll late-line patients with MSS CRC without liver metastases, including those with peritoneal metastasis/involvement.Dose and Regimen: Phase 2 dose optimization cohort will randomize patients to either 10 mg/kg or 20 mg/kg of muzastotug in combination with pembrolizumab, using an induction-maintenance regimen, without cycle limitations of muzastotug.Phase 2 Trial Design: Up to 30 patients will be enrolled in each arm of the Phase 2 study, without a requirement for a muzastotug monotherapy arm.Phase 3 Trial Design: The FDA agreed with Adagene’s proposed standard-of-care (SOC) control arm for the Phase 3 clinical trial and confirmed that a muzastotug monotherapy arm was also not required.Phase 2 Endpoints: The primary endpoint of the Phase 2 trial will be overall response rate (ORR). Secondary endpoints include duration of response (DOR), progression-free survival (PFS), and overall survival (OS).Phase 3 Endpoints: The primary endpoint of the Phase 3 trial will be OS. Secondary endpoints will include PFS, DOR and ORR. Phase 1b/2 Trial

As reported at ASCO in June 2025, in the Phase 1b/2 trial (NCT05405595), a total of 67 MSS CRC patients with no liver metastases including those with peritoneal involvement were treated with muzastotug at a dose of either 10 mg/kg or 20 mg/kg, in combination with pembrolizumab: 200 mg, Q3W. The 10 mg/kg dose was administered once every three weeks or once every six weeks. The 20 mg/kg dose was administered once as a loading dose, followed by 10 mg/kg every three weeks, or 20 mg/kg as a consistent dose every six weeks.

In the dose expansion phase of the study, patients in the 10 mg/kg Q3W cohort demonstrated an overall response rate (ORR) of 17% and patients in the 20 mg/kg cohorts demonstrated a confirmed ORR of 29%. Median duration of response (DoR) in the 10 mg/kg cohorts was 6.2 months, while the mDoR was not yet reached in the 20 mg/kg cohorts and all the responses were ongoing. Median overall survival (OS) for the 10 mg/kg cohorts was 19.4 months, comparing favorably with current treatments and historical benchmarks. Median OS for the 20 mg/kg cohorts has not yet been reached.

Both 20 mg/kg cohorts, with either a 20 mg/kg loading dose followed by 10 mg/kg Q3W, or 20 mg/kg as a consistent dose Q6W, achieved equivalent ORRs at 29%, while adverse events were less severe and seen less frequently with Q6W dosing compared to a 20mg/kg loading dose followed by 10mg/kg Q3W.

The ASCO 2025 poster and presentation can be found on the company’s website. The company anticipates providing additional updates on the Phase 1b/2 study in the coming months.    

About Adagene
Adagene Inc. (Nasdaq: ADAG) is a platform-driven, clinical-stage biotechnology company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. Adagene combines computational biology and artificial intelligence to design novel antibodies that address globally unmet patient needs. The company has forged strategic collaborations with reputable global partners that leverage its SAFEbody precision masking technology in multiple approaches at the vanguard of science.

Powered by its proprietary Dynamic Precision Library (DPL) platform, composed of NEObody™, SAFEbody, and POWERbody™ technologies, Adagene’s highly differentiated pipeline features novel immunotherapy programs. The company’s SAFEbody technology is designed to address safety and tolerability challenges associated with many antibody therapeutics by using precision masking technology to shield the binding domain of the biologic therapy. Through activation in the tumor microenvironment, this allows for tumor-specific targeting of antibodies, while minimizing on-target off-tumor toxicity in healthy tissues.

Adagene’s lead clinical program, ADG126 (muzastotug), is a masked, anti-CTLA-4 SAFEbody that targets a unique epitope of CTLA-4 in regulatory T cells (Tregs) in the tumor microenvironment. ADG126 is currently in phase 1b/2 clinical studies in combination with anti-PD-1 therapy, particularly focused on Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC). Validated by ongoing clinical research, the SAFEbody platform can be applied to a wide variety of antibody-based therapeutic modalities, including Fc empowered antibodies, antibody-drug conjugates, and bi/multispecific T-cell engagers.

For more information, please visit: https://investor.adagene.com.
Follow Adagene on WeChat, LinkedIn and X.

SAFEbody® is a registered trademark in the United States, China, Australia, Japan, Singapore, and the European Union.

KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

Investor Contacts:

Raymond Tam
[email protected]

Corey Davis
LifeSci Advisors
[email protected]
2025-10-31 11:16 6mo ago
2025-10-31 07:00 6mo ago
Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2025 stocknewsapi
FOLD
October 31, 2025 07:00 ET

 | Source:

Amicus Therapeutics, Inc.

PRINCETON, N.J., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences in November.

2025 UBS Global Healthcare Conference in Palm Beach Gardens, FL on Monday, November 10, 2025, at 2:45 p.m. ETJefferies Global Healthcare Conference 2025 in London, U.K. on Tuesday, November 18, 2025, at 4:30 p.m. GMT A live audio webcast of each presentation can also be accessed via the investors section of the Amicus Therapeutics corporate website at https://ir.amicusrx.com/events-and-presentations.

About Amicus Therapeutics
Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a pipeline of cutting-edge, first- or best-in-class medicines for rare diseases. For more information please visit the company’s website at www.amicusrx.com, and follow on LinkedIn.

CONTACT:

Investors:
Amicus Therapeutics
Andrew Faughnan
Vice President, Investor Relations
[email protected]
(609) 662-3809

Media:
Amicus Therapeutics
Brendan McEvoy
Executive Director, External Communications
[email protected]
(609) 662-5005

FOLD–G
2025-10-31 11:16 6mo ago
2025-10-31 07:00 6mo ago
Perspective Therapeutics to Participate in Upcoming November Conferences stocknewsapi
CATX
October 31, 2025 07:00 ET

 | Source:

Perspective Therapeutics, Inc.

SEATTLE, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that members of its senior leadership team will participate in and be available for one-on-one meetings with investors at the following upcoming conferences:

Truist Securities BioPharma Symposium – 1x1 only
Date: Thursday, November 6, 2025
Location: New York, NY

UBS Global Healthcare Conference – Fireside Chat
Date: Tuesday, November 11, 2025
Time: 4:15- 4:50 p.m. ET
Location: Palm Beach, FL

About Perspective Therapeutics, Inc.

Perspective Therapeutics, Inc. is a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body. The Company has proprietary technology that utilizes the alpha-emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. The Company is also developing complementary imaging diagnostics that incorporate the same targeting moieties, which provides the opportunity to personalize treatment and optimize patient outcomes. This "theranostic" approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity.

The Company's neuroendocrine tumor (VMT-α-NET), melanoma (VMT01), and solid tumor (PSV359) programs are in Phase 1/2a imaging and therapy trials in the U.S. The Company is growing its regional network of drug product candidate finishing facilities, enabled by its proprietary 212Pb generator, to deliver patient-ready product candidates for clinical trials and commercial operations.

For more information, please visit the Company's website at www.perspectivetherapeutics.com.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include statements concerning, among other things, the Company's ability to pioneer advanced treatments for cancers throughout the body; the ability of the Company's proprietary technology that utilizes the alpha-emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties; the Company’s prediction that the use of complementary imaging diagnostics that incorporate the same targeting moieties provides the opportunity to personalize treatment and optimize patient outcomes; the Company's belief that its "theranostic" approach enables the ability to see a specific tumor and then treat it to potentially improve efficacy and minimize toxicity; the Company's ability to grow its regional network of drug product candidate finishing facilities, enabled by its proprietary 212Pb generator, to deliver patient-ready product candidates for clinical trials and commercial operations; and other statements that are not historical fact.

These forward-looking statements involve risks and uncertainties that could cause the Company's actual results to differ materially from the results described in or implied by the forward-looking statements. Certain factors that may cause the Company's actual results to differ materially from those expressed or implied in the forward-looking statements in this press release are described under the heading "Risk Factors" in the Company's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC"), in the Company's other filings with the SEC, and in the Company's future reports to be filed with the SEC and available at www.sec.gov. Forward-looking statements contained in this news release are made as of this date. Unless required to do so by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Media and Investor Relations Contacts:

Perspective Therapeutics IR:
Annie J. Cheng, CFA
[email protected]

Russo Partners, LLC
Nic Johnson
[email protected]
2025-10-31 11:16 6mo ago
2025-10-31 07:00 6mo ago
Mesa Air Group enters into an Amendment to its Loan Agreement with the United States Treasury and Provides Update to its Pending Merger with Republic Airways stocknewsapi
MESA
US Treasury Loan Update PHOENIX, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Mesa Air Group, Inc. (NASDAQ: MESA) (“Mesa” or the “Company”) today announced that it has entered into an Amendment (the “Amendment”) to its Loan and Guarantee Agreement, dated as of October 30, 2020 (as theretofore amended, the “Loan Agreement”), among the Company, Mesa Airlines, the Guarantors party thereto from time to time, Jefferies Capital Services, LLC (as successor in interest to the United States Department of the Treasury) (the “Lender” or “Jefferies”), and The Bank of New York Mellon as Administrative Agent and Collateral Agent (the “Agents”) (collectively, the “Parties”). Under the terms of the Amendment, Jefferies agreed to: extend the Maturity Date of the Loan Agreement from October 30, 2025 to November 28, 2025, subject to the Company's further right to extend the Maturity Date by 30 days by providing notice to the Administrative Agent by no later than November 27, 2025; reduce the interest rate under the Loan Agreement to zero percent (0%) for a period of 90 days from the date of the Amendment; waive certain restrictions in the Loan Agreement and the collateral coverage ratio and minimum liquidity tests through the Maturity Date; and subject to the payment in full of the obligations under the Loan Agreement on the Maturity Date, reduce the principal amount of the obligations under the Loan Agreement by $12.3 million.
2025-10-31 11:16 6mo ago
2025-10-31 07:00 6mo ago
Dupixent® (dupilumab) Wins Prestigious 2025 Prix Galien USA Best Biotechnology Product Award stocknewsapi
REGN
Award recognizes the groundbreaking science of Dupixent and its transformational impact on multiple rare and common allergic and atopic conditions 

First and only therapy to specifically target the IL-4 and IL-13 signaling pathway, a key driver of type 2 inflammation that contributes to multiple conditions

TARRYTOWN, N.Y., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that Dupixent® (dupilumab) has been recognized as the “Best Biotechnology Product” of 2025 by the Galien Foundation, which acknowledges extraordinary scientific innovations that improve the human condition. The Prix Galien USA Award was presented in a ceremony in New York City last night and is the second “Best Biotechnology Product” award for Regeneron following the 2022 recognition of Inmazeb® (atoltivimab, maftivimab, and odesivimab-ebgn).

“We are honored that the Galien Foundation has recognized Dupixent, which was invented by Regeneron through decades of tireless work by our talented scientists,” said George D. Yancopoulos, M.D., Ph.D., Board co-Chair, President and Chief Scientific Officer at Regeneron, and a principal inventor of Dupixent. “Dupixent is a true ‘first-in-class’ breakthrough that can treat multiple serious diseases, and has helped re-define our understanding of allergic and atopic diseases by showing that these often disparate-appearing conditions can share the same driving mechanism of type 2 inflammation. Today, more than 1 million patients around the world are currently being treated with Dupixent, and we are committed to helping even more with eight approved indications globally and additional indications in clinical development.”

Dupixent was conceived under a unifying scientific hypothesis that predicted many allergic and atopic diseases are driven by excess interleukin-4 (IL-4) and interleukin-13 (IL-13). Dupixent Phase 3 trials in eight different atopic and allergic diseases have since demonstrated significant clinical benefits in support of this hypothesis. In 2017, Dupixent became the first dual blocker of IL-4 and IL-13 approved by the U.S. Food and Drug Administration (FDA) and remains the only FDA-approved medicine that blocks both of these factors.

Dupixent is approved for eight indications globally – ranging from rare to common conditions. These include the 2024 FDA approval of Dupixent as an add-on maintenance treatment for adults with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype – the first biologic medicine approved in the U.S. for these patients. Dupixent is also approved for specific patients (see U.S. Indications below for details) with atopic dermatitis, asthma, eosinophilic esophagitis, chronic rhinosinusitis with nasal polyps, chronic spontaneous urticaria, bullous pemphigoid and prurigo nodularis.

The most common side effects of Dupixent are as follows: injection site reactions, upper respiratory tract infections, eye problems (including eye and eyelid inflammation, redness, swelling, itching, eye infection, dry eye, and blurred vision), herpes virus infections, common cold symptoms (nasopharyngitis), cold sores in your mouth or on your lips, high count of a certain white blood cell (eosinophilia), dizziness, muscle pain, diarrhea, pain in the throat (oropharyngeal pain), gastritis, joint pain (arthralgia), trouble sleeping (insomnia), toothache, parasitic (helminth) infections, viral infection, back pain, inflammation inside the nose (rhinitis), headache, and urinary tract infection.

About Dupixent
Dupixent, which was invented using Regeneron’s proprietary VelocImmune® technology, is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways and is not an immunosuppressant. The Dupixent development program has shown significant clinical benefit and a decrease in type 2 inflammation in Phase 3 trials, establishing that IL-4 and IL-13 are two of the key and central drivers of the type 2 inflammation that plays a major role in multiple related and often co-morbid diseases.

Dupixent has received regulatory approvals in more than 60 countries in one or more indications including certain patients with atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), eosinophilic esophagitis (EoE), prurigo nodularis, chronic spontaneous urticaria (CSU), chronic obstructive pulmonary disease (COPD), and bullous pemphigoid (BP) in different age populations. More than 1,000,000 patients are being treated with Dupixent globally.1

Dupilumab Development Program 
Dupilumab is being jointly developed by Regeneron and Sanofi under a global collaboration agreement. To date, dupilumab has been studied across more than 60 clinical trials involving more than 10,000 patients with various chronic diseases driven in part by type 2 inflammation. 

In addition to the currently approved indications, Regeneron and Sanofi are studying dupilumab in a broad range of diseases driven by type 2 inflammation or other allergic processes in Phase 3 trials, including chronic pruritus of unknown origin and lichen simplex chronicus. These potential uses of dupilumab are currently under clinical investigation, and the safety and efficacy in these conditions have not been fully evaluated by any regulatory authority.

U.S. INDICATIONS 
DUPIXENT is a prescription medicine used:

to treat adults and children 6 months of age and older with moderate-to-severe eczema (atopic dermatitis or AD) that is not well controlled with prescription therapies used on the skin (topical), or who cannot use topical therapies. DUPIXENT can be used with or without topical corticosteroids. It is not known if DUPIXENT is safe and effective in children with AD under 6 months of age.with other asthma medicines for the maintenance treatment of moderate-to-severe eosinophilic or oral steroid dependent asthma in adults and children 6 years of age and older whose asthma is not controlled with their current asthma medicines. DUPIXENT helps prevent severe asthma attacks (exacerbations) and can improve your breathing. DUPIXENT may also help reduce the amount of oral corticosteroids you need while preventing severe asthma attacks and improving your breathing. It is not known if DUPIXENT is safe and effective in children with asthma under 6 years of age.with other medicines for the maintenance treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) in adults and children 12 years of age and older whose disease is not controlled. It is not known if DUPIXENT is safe and effective in children with CRSwNP under 12 years of age.to treat adults and children 1 year of age and older with eosinophilic esophagitis (EoE), who weigh at least 33 pounds (15 kg). It is not known if DUPIXENT is safe and effective in children with EoE under 1 year of age, or who weigh less than 33 pounds (15 kg).to treat adults with prurigo nodularis (PN). It is not known if DUPIXENT is safe and effective in children with PN under 18 years of age.with other medicines for the maintenance treatment of adults with inadequately controlled chronic obstructive pulmonary disease (COPD) and a high number of blood eosinophils (a type of white blood cell that may contribute to your COPD). DUPIXENT is used to reduce the number of flare-ups (the worsening of your COPD symptoms for several days) and can improve your breathing. It is not known if DUPIXENT is safe and effective in children with COPD under 18 years of age.to treat adults and children 12 years of age and older with chronic spontaneous urticaria (CSU) who continue to have hives that are not controlled with H1 antihistamine treatment. It is not known if DUPIXENT is safe and effective in children with CSU under 12 years of age, or who weigh less than 66 pounds (30 kg).to treat adults with bullous pemphigoid (BP). It is not known if DUPIXENT is safe and effective in children with BP under 18 years of age. DUPIXENT is not used to relieve sudden breathing problems and will not replace an inhaled rescue medicine or to treat any other forms of hives (urticaria).

IMPORTANT SAFETY INFORMATION

Do not use if you are allergic to dupilumab or to any of the ingredients in DUPIXENT®.

Before using DUPIXENT, tell your healthcare provider about all your medical conditions, including if you:

have eye problems.have a parasitic (helminth) infection.are scheduled to receive any vaccinations. You should not receive a “live vaccine” right before and during treatment with DUPIXENT.are pregnant or plan to become pregnant. It is not known whether DUPIXENT will harm your unborn baby. A pregnancy registry for women who take DUPIXENT during pregnancy collects information about the health of you and your baby. To enroll or get more information call 1-877-311-8972 or go to https://mothertobaby.org/ongoing-study/dupixent/. are breastfeeding or plan to breastfeed. It is not known whether DUPIXENT passes into your breast milk. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Especially tell your healthcare provider if you are taking oral, topical, or inhaled corticosteroid medicines; have asthma and use an asthma medicine; or have AD, CRSwNP, EoE, PN, COPD, CSU, or BP and also have asthma. Do not change or stop your other medicines, including corticosteroid medicine or other asthma medicine, without talking to your healthcare provider. This may cause other symptoms that were controlled by those medicines to come back.

DUPIXENT can cause serious side effects, including:

Allergic reactions. DUPIXENT can cause allergic reactions, including skin reactions, that can sometimes be severe. Stop using DUPIXENT and tell your healthcare provider or get emergency help right away if you get any of the following signs or symptoms: breathing problems or wheezing, swelling of the face, lips, mouth, tongue or throat, fainting, dizziness, feeling lightheaded, fast pulse, fever, hives, skin rash, including rash that looks like a bullseye, painful red or blue bumps under the skin, or red pus-filled spots on the skin, general ill feeling, itching, swollen lymph nodes, nausea or vomiting, joint pain, or cramps in your stomach area.Eye problems. Tell your healthcare provider if you have any new or worsening eye problems, including eye pain or changes in vision, such as blurred vision. Your healthcare provider may send you to an ophthalmologist for an exam if needed.Inflammation of your blood vessels. Rarely, this can happen in people with asthma who receive DUPIXENT. This may happen in people who also take a steroid medicine by mouth that is being stopped or the dose is being lowered. Tell your healthcare provider right away if you get: rash, chest pain, worsening shortness of breath, brown or dark colored urine, persistent fever, or a feeling of pins and needles or numbness of your arms or legs.Psoriasis. This can happen in people with atopic dermatitis and asthma who receive DUPIXENT. Tell your healthcare provider about any new skin symptoms. Your healthcare provider may send you to a dermatologist for an examination if needed.Joint aches and pain. Some people who use DUPIXENT have had trouble walking or moving due to their joint symptoms, and in some cases needed to be hospitalized. Tell your healthcare provider about any new or worsening joint symptoms. Your healthcare provider may stop DUPIXENT if you develop joint symptoms.
The most common side effects include:

Eczema: injection site reactions, eye problems, including eye and eyelid inflammation, redness, swelling, itching, eye infection, dry eye, and blurred vision, cold sores in your mouth or on your lips, and high count of a certain white blood cell (eosinophilia).Asthma: injection site reactions, high count of a certain white blood cell (eosinophilia), pain in the throat (oropharyngeal pain), and parasitic (helminth) infections.Chronic Rhinosinusitis with Nasal Polyps: injection site reactions, eye problems, including eye and eyelid inflammation, redness, swelling, itching, eye infection, and blurred vision, high count of a certain white blood cell (eosinophilia), stomach problems (gastritis), joint pain (arthralgia), trouble sleeping (insomnia), and toothache.Eosinophilic Esophagitis: injection site reactions, upper respiratory tract infections, cold sores in your mouth or on your lips, and joint pain (arthralgia).Prurigo Nodularis: eye problems, including eye and eyelid inflammation, redness, swelling, itching, and blurred vision, herpes virus infections, common cold symptoms (nasopharyngitis), dizziness, muscle pain, and diarrhea.Chronic Obstructive Pulmonary Disease: injection site reactions, common cold symptoms (nasopharyngitis), high count of a certain white blood cell (eosinophilia), viral infection, back pain, inflammation inside the nose (rhinitis), diarrhea, stomach problems (gastritis), joint pain (arthralgia), toothache, headache, and urinary tract infection.Chronic Spontaneous Urticaria: injection site reactions.Bullous Pemphigoid: joint pain (arthralgia), eye problems, including eye and eyelid inflammation, redness, swelling, itching, and blurred vision, and herpes virus infections. Tell your healthcare provider if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of DUPIXENT. Call your doctor for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Use DUPIXENT exactly as prescribed by your healthcare provider. It’s an injection given under the skin (subcutaneous injection). Your healthcare provider will decide if you or your caregiver can inject DUPIXENT. Do not try to prepare and inject DUPIXENT until you or your caregiver have been trained by your healthcare provider. In children 12 years of age and older, it’s recommended DUPIXENT be administered by or under supervision of an adult. In children 6 months to less than 12 years of age, DUPIXENT should be given by a caregiver.

Please see accompanying full Prescribing Information including Patient Information.

About Regeneron’s VelocImmune Technology
Regeneron's VelocImmune technology utilizes a proprietary genetically engineered mouse platform endowed with a genetically humanized immune system to produce optimized fully human antibodies. When Regeneron's co-Founder, President and Chief Scientific Officer George D. Yancopoulos was a graduate student with his mentor Frederick W. Alt in 1985, they were the first to envision making such a genetically humanized mouse, and Regeneron has spent decades inventing and developing VelocImmune and related VelociSuite® technologies. Dr. Yancopoulos and his team have used VelocImmune technology to create a substantial proportion of all original, FDA-approved fully human monoclonal antibodies. This includes Dupixent® (dupilumab), Libtayo® (cemiplimab-rwlc), Praluent® (alirocumab), Kevzara® (sarilumab), Evkeeza® (evinacumab-dgnb), Inmazeb® (atoltivimab, maftivimab and odesivimab-ebgn) and Veopoz® (pozelimab-bbfg). In addition, REGEN-COV® (casirivimab and imdevimab) had been authorized by the FDA during the COVID-19 pandemic until 2024.

About Regeneron
Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases.

Regeneron pushes the boundaries of scientific discovery and accelerates drug development using our proprietary technologies, such as VelociSuite®, which produces optimized fully human antibodies and new classes of bispecific antibodies. We are shaping the next frontier of medicine with data-powered insights from the Regeneron Genetics Center® and pioneering genetic medicine platforms, enabling us to identify innovative targets and complementary approaches to potentially treat or cure diseases.

For more information, please visit, www.Regeneron.com or follow Regeneron on LinkedIn, Instagram, Facebook or X.

Regeneron Forward-Looking Statements and Use of Digital Media 
This press release includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”), and actual events or results may differ materially from these forward-looking statements. Words such as “anticipate,” “expect,” “intend,” “plan,” “believe,” “seek,” “estimate,” variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. These statements concern, and these risks and uncertainties include, among others, the nature, timing, and possible success and therapeutic applications of products marketed or otherwise commercialized by Regeneron and/or its collaborators or licensees (collectively, “Regeneron’s Products”) and product candidates being developed by Regeneron and/or its collaborators or licensees (collectively, “Regeneron’s Product Candidates”) and research and clinical programs now underway or planned, including without limitation Dupixent® (dupilumab); the likelihood, timing, and scope of possible regulatory approval and commercial launch of Regeneron’s Product Candidates and new indications for Regeneron’s Products, including Dupixent for the treatment of chronic pruritus of unknown origin, lichen simplex chronicus, and other potential indications; uncertainty of the utilization, market acceptance, and commercial success of Regeneron’s Products (such as Dupixent) and Regeneron’s Product Candidates and the impact of studies (whether conducted by Regeneron or others and whether mandated or voluntary), including the studies discussed or referenced in this press release, on any of the foregoing; the ability of Regeneron’s collaborators, licensees, suppliers, or other third parties (as applicable) to perform manufacturing, filling, finishing, packaging, labeling, distribution, and other steps related to Regeneron’s Products and Regeneron’s Product Candidates; the ability of Regeneron to manage supply chains for multiple products and product candidates and risks associated with tariffs and other trade restrictions; safety issues resulting from the administration of Regeneron’s Products (such as Dupixent) and Regeneron’s Product Candidates in patients, including serious complications or side effects in connection with the use of Regeneron’s Products and Regeneron’s Product Candidates in clinical trials; determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron’s ability to continue to develop or commercialize Regeneron’s Products and Regeneron’s Product Candidates; ongoing regulatory obligations and oversight impacting Regeneron’s Products, research and clinical programs, and business, including those relating to patient privacy; the availability and extent of reimbursement or copay assistance for Regeneron’s Products from third-party payors and other third parties, including private payor healthcare and insurance programs, health maintenance organizations, pharmacy benefit management companies, and government programs such as Medicare and Medicaid; coverage and reimbursement determinations by such payors and other third parties and new policies and procedures adopted by such payors and other third parties; changes to drug pricing regulations and requirements and Regeneron’s pricing strategy; other changes in laws, regulations, and policies affecting the healthcare industry; competing drugs and product candidates that may be superior to, or more cost effective than, Regeneron’s Products and Regeneron’s Product Candidates (including biosimilar versions of Regeneron’s Products); the extent to which the results from the research and development programs conducted by Regeneron and/or its collaborators or licensees may be replicated in other studies and/or lead to advancement of product candidates to clinical trials, therapeutic applications, or regulatory approval; unanticipated expenses; the costs of developing, producing, and selling products; the ability of Regeneron to meet any of its financial projections or guidance and changes to the assumptions underlying those projections or guidance; the potential for any license, collaboration, or supply agreement, including Regeneron’s agreements with Sanofi and Bayer (or their respective affiliated companies, as applicable), to be cancelled or terminated; the impact of public health outbreaks, epidemics, or pandemics on Regeneron's business; and risks associated with litigation and other proceedings and government investigations relating to the Company and/or its operations (including the pending civil proceedings initiated or joined by the U.S. Department of Justice and the U.S. Attorney's Office for the District of Massachusetts), risks associated with intellectual property of other parties and pending or future litigation relating thereto (including without limitation the patent litigation and other related proceedings relating to EYLEA® (aflibercept) Injection), the ultimate outcome of any such proceedings and investigations, and the impact any of the foregoing may have on Regeneron’s business, prospects, operating results, and financial condition. A more complete description of these and other material risks can be found in Regeneron’s filings with the U.S. Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2024 and its Form 10-Q for the quarterly period ended September 30, 2025. Any forward-looking statements are made based on management’s current beliefs and judgment, and the reader is cautioned not to rely on any forward-looking statements made by Regeneron. Regeneron does not undertake any obligation to update (publicly or otherwise) any forward-looking statement, including without limitation any financial projection or guidance, whether as a result of new information, future events, or otherwise.

Regeneron uses its media and investor relations website and social media outlets to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Regeneron is routinely posted and is accessible on Regeneron's media and investor relations website (https://investor.regeneron.com) and its LinkedIn page (https://www.linkedin.com/company/regeneron-pharmaceuticals).

______________________________

1 Data on File